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ABSTRACT 
As genetic testing technologies continue to evolve, new opportunities for cancer risk 
assessment and prevention may become available. Because of this, it is necessary to evaluate the 
process of patient recontact for the purpose of offering additional genetic testing. Limited 
information exists regarding patients’ expectations and preferences for recontact by their genetics 
providers. In addition, there is limited literature exploring the current practice of recontact by 
genetics providers and their attitudes regarding the duty to recontact patients. This study evaluated 
both patient and genetics providers’ attitudes regarding recontact. Questionnaires were sent to 
1000 patients previously tested for BRCA1/2 between the years 2007-2012 at the UPMC Cancer 
Genetics Program that inquired about their expectations and preferences for recontact. 
Questionnaires were also sent to 490 members of the National Society of Genetic Counselors 
Cancer Risk Assessment Special Interest Group that inquired about current practice of patient 
recontact and attitudes regarding clinical practice guidelines and ethical responsibility to recontact 
patients. This study found that patients believed that their genetics providers hold more 
responsibility to keep patients updated about new genetic discoveries than other providers and the 
patients themselves. The data supports that patients’ preferences for recontact include personalized 
information only when new information is discovered and preferences were not influenced by 
genetic testing results. In addition, the study found that genetics providers believe there is some 
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ethical duty to keep patients informed of new genetic information, and the majority of providers 
have previously recontacted patients for this purpose, but do not have formalized systems of 
recontact established. Resources, such as staff, monetary support, and database access were found 
to influence the practice of recontact by genetics providers, and the data suggests that database 
access is a significant component for genetics providers to have established systems of recontact. 
The majority of genetics providers did not believe patient recontact should be standard of care, 
however, desired clinical practice guidelines. This research is significant to the field of public 
health as it clarified patient expectations regarding recontact and has implications that may aid in 
the development of recontacting strategies for genetics providers.  
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1.0  INTRODUCTION 
This research study was conducted to assess patients’ and cancer genetics providers’ attitudes 
regarding the practice of recontact when new genetic discoveries have been made and/or new 
genetic testing becomes available.  
The research study focused on patients who were previously tested for mutations in the 
BRCA1 and BRCA2 genes, which account for the majority of Hereditary Breast and Ovarian 
Cancer Syndrome (HBOC)1. HBOC is an autosomal dominant condition characterized by an 
increased risk for breast and ovarian cancer along with other cancers, including prostate, pancreas, 
and melanoma1. BRCA1 and BRCA2 are tumor suppressor genes, and mutations within those genes 
lead to an increased risk for tumor growth and development1. It is estimated that approximately 
1/400 to 1/800 individuals carry a BRCA1/2 mutation in the general population2. In addition, it is 
estimated that approximately 250,000 individuals undergo genetic testing for BRCA1/2 each year3.   
Individuals who are suspected of having a hereditary predisposition to certain cancers 
within their family are typically referred to a medical geneticist and/or genetic counselor. During 
a genetic counseling consultation, a detailed medical and family history are obtained. The National 
Comprehensive Cancer Network (NCCN) have specific guidelines for whom genetic testing 
should be offered to4. The NCCN guidelines take into account personal and family history of 
HBOC-related cancers. If a patient pursues genetic testing, they are often times notified of the 
results either by phone or an additional in person consultation. A summary of the patient’s genetic 
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testing results and current cancer screening recommendations are provided to the patient, the 
patient’s primary care physician, and if necessary, other doctors involved in the patient’s care. 
When a patient’s results reveal a positive gene mutation, this is often an answer for their personal 
and family cancer history. When a patient’s results are negative (no mutation detected) or 
inconclusive, there is often much left to be answered. Due to the volume of patients who receive 
genetic counseling, it is not possible for genetics providers to recontact all patients who have a 
negative test result when new genetic testing becomes available. Therefore, most genetics 
providers will recommend that patients be responsible for recontact and that they should 
communicate with their primary care physicians or specialists regarding new information.  
The American College of Medical Genetics (ACMG) have published guidelines that 
support this concept5. These guidelines state that it is the patient and the primary care physician’s 
responsibility to seek up-to-date information regarding genetic testing. Only in situations where a 
genetic counselor or medical geneticist provides ongoing care, do they hold the primary 
responsibility. This is the minority of cases within a cancer genetics setting. The ACMG guidelines 
have been established to protect genetics health care providers from the burden of recontact and 
from liability issues that may be raised.  
Understanding the patients’ perspective for recontact is an important factor to consider 
when determining the success of such a policy. As genetic testing continues to evolve, especially 
with the evolution of next generation sequencing panels, whole exome and genome sequencing, 
the issue of recontact will become more complex. If the policy for the “duty to recontact” were to 
change, perhaps holding the genetics providers to a higher responsibility, it would be essential to 
know if and how patients would prefer to be recontacted. This study aims to understand patients’ 
current expectations regarding recontact and their preferred methods of recontact if it were to be 
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initiated. Similarly, systems of recontact would need to be developed, taking into account the 
limited resources available to many genetics providers. This study was also designed to determine 
what methods genetics providers currently use for purposes of recontacting their patients and 
assessing their current attitudes regarding the responsibility to recontact patients.  
1.1 SPECIFIC AIMS AND HYPOTHESES  
Specific Aim 1: Determine patients’ expectations and preferences regarding recontact, including 
factors which influence their decision making, and whether preferences differ based 
on test results.  
Hypothesis:   Patients’ perceptions of their primary care providers’ knowledge of genetic testing 
influences their expectations for who is believed most responsible to provide 
information on new genetic discoveries. Different genetic testing results will 
influence patients’ expectations and preferences for recontact.  
Plan:  Questionnaires will inquire about patient’s relationship with their primary care 
providers, expectations for recontact by their primary care providers, preferences 
and motivations for recontact, and recall of recontact recommendations from prior 
genetics consultations. Survey responses will be analyzed to identify common 
trends.  
Specific Aim 2: Determine current practices of cancer genetics providers regarding recontact for 
the purpose of additional genetic testing opportunities. Assess genetics providers’ 
attitudes regarding the need for clinical practice guidelines concerning recontact and 
their attitudes in terms of ethical responsibility to recontact.  
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Hypothesis:  Providers believe that patients hold the most responsibility for staying informed of 
new genetic discoveries. While genetics providers believe there is some duty to 
recontact patients, limited resources impact their ability and means to do so.  
Plan:  Questionnaires will inquire about whether methods of recontact have been 
established by genetic healthcare providers and if so, what methods have been 
utilized. Theoretical considerations regarding recontact will be analyzed.  
1.2 HEREDITARY BREAST AND OVARIAN CANCER BACKGROUND  
1.2.1 Cancer Overview  
In the United States, approximately one- half of all men and one -third of all women are at risk of 
developing cancer throughout their lifetime6. Cancer arises from the accumulation of genetic 
mutations, either germline or somatic, in major cancer predisposition genes that are responsible 
for cell cycle progression and DNA repair7; 8. These genes include proto-oncogenes, tumor 
suppressor genes, and DNA repair genes7; 8.  
Breast cancer is the second most common cancer among women in the United States6. It is 
estimated that approximately 1 in 8 women (12%) will develop invasive breast cancer throughout 
her lifetime, and the median age of diagnosis for breast cancer is 61 years6. The 5-year survival 
rate for breast cancer in women ranges from almost 100% (stage I) to 22% (stage IV)6.  Male breast 
cancer is less common, and it is estimated that approximately 1 in 1000 (0.1%) men will develop 
breast cancer throughout his lifetime9. The 5-year survival rate for breast cancer in males ranges 
from 100% (stage I) to 20% (stage IV)9. 
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Ovarian cancer is the eighth most common cancer among women in the United States, 
excluding skin cancer. It is estimated that approximately 1 in 73 women (1.4%) will develop 
ovarian cancer throughout her lifetime and the median age of diagnosis for ovarian cancer is 63 
years10. The 5-year survival rate for ovarian cancer ranges from 89% (stage I) to 18% (stage IV)10.  
1.2.2 Cancer Etiology and Risk Factors 
There are three main etiologies of the development of cancer, as shown by Figure 1. The 
development of cancer may be a sporadic occurrence, a familial predisposition, or a hereditary 
predisposition8; 11.  
 
Figure 1. Etiologies of Cancer 
 
The majority of cancers that occur are sporadic (60%), meaning that they occur by chance. 
Sporadic cancers are the result of the accumulation of somatic mutations in major cancer 
preposition genes8. These mutations are primarily acquired from environmental exposures and age 
related risk factors8. The most significant risk factors for the development of breast cancer are 
being female and aging6. Other factors that modify breast cancer risk within the general population 
are:  
 
Sporadic
60%
Familial
30%
Hereditary
7-10%
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o Hormonal Factors6 
o Women with early menarche (<12 years) and older age at menopause (>55 years) 
have a slightly higher risk for developing breast cancer, which is thought to be 
related to the length of exposure time to cycling ovarian hormones12.   
o Age at first live birth (>35 years) is associated with increased risk for breast 
cancer (OR 1.26). In addition,  women who’ve had two or more pregnancies have 
a decreased risk of breast cancer, while nulliparous women are at an increased 
risk, compared to uniparous women.13.  
o Breast feeding reduces breast cancer risk by approximately 4.3% for every 12 
months and a greater reduction in risk is associated with longer duration14. 
o Oral contraceptive use is associated with a slightly elevated risk of developing 
breast cancer (RR:1.24) as compared to those who have never used oral 
contraceptives. The risk  is normalized after 10 years of discontinued use15.  
o Long term  non-menopausal hormone replacement therapy use has been 
associated with an increased risk of breast cancer (RR:1.35)16. 
o Benign breast conditions6  
o Personal history of lobular carcinoma in situ (LCIS) can increase the risk of 
developing invasive breast cancer by 7-10 times that of women without a history 
of LCIS17.   
o Personal history of atypical ductal/lobular hyperplasia is associated with a 3-4 
fold increased risk for breast cancer17; 18.  
o Women with dense breast tissue have a risk of breast cancer 4-6 times that of a 
women with less dense breast tissue19. 
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o Personal history of breast cancer6  
o A woman with breast cancer in one breast has a 3-4 fold increased risk of 
developing another primary breast cancer6. 
o Exposures6  
o High-dose radiation therapy to the chest increases risk of breast cancer. The risk 
is highest when exposed during childhood or adolescence20.  
o In utero exposure to diethylstilbestrol (DES) increases breast cancer risk by 
approximately 3.9% in women older than 40 years21. 
o Consumption of 2-5 alcoholic drinks per day increases breast cancer risk by 1.5 
times as compared to those who do not drink alcohol22.  
o Family history of breast cancer6 
o The risk of developing breast cancer is 1.8 times higher for women with one 1st 
degree female relative with breast cancer23. 
o The risk of developing breast cancer is 2.9 times higher for women with two first 
degree relatives with breast cancer and 3.9 times higher for women with 3 or 
more first degree relatives with breast cancer23. 
Risk factors associated with ovarian cancer in the general population include: 
o Hormonal factors10  
o Having a first pregnancy after the age of 35 is twice as protective against ovarian 
cancer as a pregnancy younger than 25 years of age.  One pregnancy lowers the 
risk by as much as 33%, and the risk decreases with each additional pregnancy24; 
25.  
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o Breastfeeding for 18 or more months may decrease the risk of ovarian cancer by 
up to 34%26. 
o Oral contraceptive use for any period of time is associated with a 34% risk 
reduction in ovarian cancer and  up to 60% risk reduction when used for 6 or 
more years24.  
o Post-menopausal estrogen replacement therapy use for more than 10 years has 
been associated with an increased risk of ovarian cancer27.  
o Clinical factors10  
o Chronic pelvic inflammatory disease and ovarian endometriosis are associated 
with a slight increased risk for ovarian cancer28; 29.  
o Tubal ligation is associated with a 34% reduction in ovarian cancer risk30 
o Exposures10  
o Talcum powder usage within the perineal area increases the risk of ovarian cancer 
by up to 33% 31. 
o Family History of ovarian cancer10  
o The lifetime risk of developing ovarian cancer is 4.3 times higher for women with 
one 1st degree relative with ovarian cancer32; 33.  
 Approximately 30% of all cancer cases are familial8. Familial cancers are clusters of cancer 
within a family that occur in a higher frequency than would be expected by chance alone8. Familial 
cancers are the result of multiple genetic factors and multiple environmental factors interacting 
over time8. Familial cancers are variable in age of onset, but overall may occur at a slightly younger 
age than sporadic cancers8.  
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 Approximately 7-10% of cancers are hereditary, meaning they are caused by inheriting a 
single genetic mutation8; 11. Many hereditary cancers develop when a germline mutation is 
inherited in a tumor suppressor gene, and the second copy of that particular gene acquires somatic 
mutations in the same cell7. This event is also known as the “Two Hit Hypothesis”, first proposed 
by Dr. Alfred Knudson in 1971 to describe inherited retinoblastoma11. Knudson proposed that 
inheriting one germline mutation (“first hit”) was not sufficient to cause carcinogenesis. Rather, 
an acquired mutation (“second hit”) within the other copy of the gene was required to lose control 
of cell division and lead to cancer development6.  
1.2.3 Hereditary Breast and Ovarian Cancer Syndrome 
The majority of Hereditary Breast and Ovarian Cancer (HBOC) cases are caused by mutations 
within the tumor suppressor genes, BRCA1 and BRCA21. Mutations within BRCA1/2 account for 
approximately 3-5% of all breast cancers and approximately 10-15% of all ovarian cancer cases34.  
The population frequency of mutations within the BRCA1 and BRCA2 genes is estimated to be 
between 1/400 to 1/8002. Mutations are found in all racial and ethnic populations. However, the 
prevalence of BRCA1/2 mutations is higher in some founder populations, such as the Ashkenazi 
Jewish population, where it is estimated that the prevalence of carrying a BRCA1/2 mutation is 
1/4035. Other founder mutations have been identified in populations from the Netherlands, Sweden, 
Hungary, Iceland, and French Canada34.  
1.2.3.1 Genetics of HBOC  
The BRCA1 gene is located on chromosome 17p2136. BRCA1 encodes the breast cancer type 1 
susceptibility protein37. BRCA1 interacts with a number of other proteins involved cell cycle 
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progression, gene transcription regulation, double stand DNA damage response and 
ubiquitination37-39. The BRCA2 gene is located on chromosome 13q1240. BRCA2 encodes the 
breast cancer type 2 susceptibility protein. BRCA2 interacts with other proteins, including those 
encoded by RAD51 and PALB2 to act in DNA repair of double stranded DNA breakage39; 40.  
Greater than 1600 mutations have been identified in BRCA1 and greater than 1800 
mutations have been identified in BRCA22. The most common types of mutations are frameshift 
deletions, insertions, and nonsense mutations resulting in premature truncation of protein 
transcription2. Approximately 12% of mutations in BRCA1/2 are the result of large deletions or 
duplications41.  
1.2.3.2 Clinical Presentation and Diagnosis  
Features that are suggestive of HBOC include early onset breast cancer (<50 years), 
bilateral breast cancer, epithelial ovarian cancer, breast and ovarian cancer diagnosed in the same 
individual, and male breast cancer4. In addition, HBOC-related cancers occurring in multiple 
family members across multiple generations within the same bloodline of a family are suggestive 
of HBOC. 
Previous studies have been performed to understand the penetrance of BRCA1/2 and 
associated cancer risks. BRCA1/2 mutations have been shown to have the most impact on breast 
and ovarian cancer risk (Table 1). The lifetime risk for developing breast cancer for a woman with 
a BRCA1/2 mutation ranges from 40-80%. In addition, the lifetime risk for developing ovarian 
cancer for a woman with a BRCA1/2 mutation ranges from 20-40%.  The range of cancer risk 
results from the incomplete penetrance seen with BRCA1/2 mutations. Penetrance has been shown 
to vary within families with the same BRCA1/2 mutation as well2. Both breast and ovarian cancer 
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risks appear higher in individuals with BRCA1 mutations compared to individuals with BRCA2 
mutations42.  
Table 1. Lifetime Breast and Ovarian Cancer Risk Associated with BRCA1/2 Mutations 
Cancer General Population Risk BRCA1/2 Mutation 
Breast Cancer  8-12%6 40-80%1 
2nd Breast Cancer  <10%43 2-3% per year44 
Ovarian Cancer  <2%10 20-40%1  
  
Additional studies have shown that mutations in BRCA1/2 can increase the lifetime risk for 
other types of cancer (Table 2).  In general, BRCA2 carriers have an increased risk for male breast 
cancer, prostate cancer, pancreatic cancer, and melanoma above that of BRCA1 carriers44.    
Table 2. Other Lifetime Cancer Risks Associated with BRCA1/2 Mutations 
Cancer General Population Risk45 BRCA1/2 Mutation 
Male Breast Cancer   <1% 7%46 
Prostate Cancer  16% 20-39%1; 44  
Pancreatic Cancer   <2% 2-7%1; 44 
Melanoma  <2% 2-5%44 
 
BRCA1/2 related breast cancers have characteristic pathology. BRCA1 related breast 
tumors are more likely to be of medullary histology and of high nuclear grade2. BRCA1 tumors are 
also more likely to be “triple negative” than sporadic tumors, meaning that the tumor is estrogen 
and progesterone receptor negative and that the tumor does not demonstrate HER2/neu over-
expression47. BRCA2 related breast cancer tumors typically have an inconsistent phenotype, 
without a characteristic histological grade or tumor classification2.  Nearly all ovarian cancers  
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associated with BRCA1/2 mutations are epithelial in origin and have high grade serous histology2. 
The most commonly associated ovarian tumors are papillary serous adenocarcinomas. Ovarian 
tumors that originate from the germ cells or stromal tissue are not associated with mutations in 
BRCA1/2.  
1.2.4 Genetic Counseling for HBOC 
The goal of genetic counseling is to educate patients about their cancer risk, help them derive 
personal meaning from this information, and empower them to make informed decisions about 
genetic testing, cancer surveillance, and cancer prevention options8. 
Genetic counseling consists of interpretation of personal and family history, cancer risk 
assessment, and psychosocial assessment8. If an individual is a candidate for genetic testing, 
informed consent is obtained. Informed consent includes proper education of cancer genetics 
including inheritance, discussion of medical management guidelines, information about the 
genetic testing process including possible test results, addressing economic and confidentiality 
concerns, discussing psychosocial issues associated with genetic testing, and identifying relevant 
resources/support for the patient48.  
1.2.4.1 Family history Interpretation and Cancer Risk Assessment  
Genetic risk assessment is the process of identifying individuals at an increased risk for familial 
or hereditary cancer predispositions8. Cancer risk assessment for HBOC includes analysis of the 
family pedigree, an individual’s personal medical history, and relevant exposures48. A targeted 
three-generation family pedigree is a useful tool to identify features that are suggestive of HBOC. 
However, there can be instances where the family pedigree is not useful in determining an 
  
13 
individual’s risk and may conceal the presence of a hereditary cancer syndrome48. These instances 
include limited knowledge of or access to family history information (including adoption), small 
family size, early deaths within a family (unrelated to cancer), or having predominately male 
relatives49.  
There are several risk calculation models available to assess the likelihood of identifying a 
BRCA1/2 mutation within a patient. Models such as BRCAPRO use Bayesian analysis of 
conditional probabilities to estimate the likelihood of a BRCA1/2 mutation based on the 
individual’s personal cancer history, family history, and Ashkenazi Jewish ancestry50. In addition, 
Myriad Prevalence Tables have been published, by Myriad Genetic Laboratories, using the data 
gained from their genetic testing services. Myriad Prevalence Tables estimate the likelihood of a 
BRCA1/2 mutation based on an individual’s personal cancer history, family history, and Ashkenazi 
Jewish ancestry and the prevalence rates of mutations among them51. A number of other BRCA1/2 
mutation probability models are available, including PennII, BOADICEA, and the Tyrer-Cuzick 
model48. These models incorporate various HBOC-related cancers in the patient, first and second 
degree relatives, along with ages of onset, and may include other personal factors52. The 
information determined by these risk calculation models provides an estimate for an individual’s 
probability of carrying a BRCA1/2 mutation, which may also be used to determine the 
appropriateness of genetic testing for certain individuals. Previously, the American Society of 
Clinical Oncology (ASCO) suggested that testing be considered for individuals whose estimated 
probability of to carry a BRCA1/2 mutation was 10% or greater53. However, many centers use the 
National Comprehensive Cancer Network guidelines when considering genetic testing4.  
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1.2.4.2 Differential Diagnosis  
As stated, HBOC accounts for the majority of hereditary breast and ovarian cancers. There are 
other less common hereditary cancer syndromes that include predispositions to breast and ovarian 
cancer52. Other hereditary cancer syndromes often have similar characteristics, including early 
onset cancers, high penetrant cancer risks, and follow an autosomal dominant pattern. Refer to 
Appendix A for an overview of other hereditary breast and ovarian cancer syndromes.  
1.2.4.3 Medical Management Options  
Management guidelines for individuals with HBOC are published by the National Comprehensive 
Cancer Network4. The guidelines for women with HBOC include:  
Breast cancer  
o Clinical breast exams, every 6-12 months, beginning at age 25 
o Mammogram and breast MRI, annually, beginning at age 25 
o Consider prophylactic mastectomy  
o Consider chemoprevention options, such as selective estrogen receptor modulators 
(Tamoxifen) or aromatase inhibitors  
Ovarian cancer 
o Prophylactic bilateral salpingo-oophorectomy (BSO), upon completion of childbearing or 
between the ages of 35 and 40 
o For those who do not elect to undergo prophylactic BSO, trans-vaginal ultrasound and 
CA-125 blood tests, every 6 months, beginning at age 30 or 5-10 years before the earliest 
ovarian cancer diagnosis in the family 
o Consider chemoprevention options, such as oral contraceptives  
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The guidelines for men with HBOC include:  
Breast cancer  
o Clinical breast exam, every 6-12 months, beginning at age 35 
o Consider baseline mammogram at age 40, and annual mammogram if excess or dense 
breast tissue is present  
Prostate cancer  
o Prostate cancer screening, including digital rectal exam and PSA measurements, 
annually, beginning at age 40 
At this time, no specific guidelines exist for pancreatic cancer and melanoma. Screening may be 
individualized based on cancers observed in the family. Annual, full-body dermatological exams 
and ophthalmologic exams may be considered for melanoma screening. Endoscopic ultrasounds, 
MRIs or other investigational protocols may be considered for pancreatic cancer detection.  
1.2.5 Genetic Testing for HBOC  
Molecular genetic testing for BRCA1/2 is available to confirm the diagnosis of HBOC, as well as 
the identification of at-risk family members. Clinical testing has been available commercially since 
October 19962. 
1.2.5.1 Recommendations and Guidelines for Genetic Testing  
Recommendations for genetic testing for cancer susceptibility are published by The American 
Society of Clinical Oncology53. These guidelines state that genetic testing should be offered when:  
o There is a personal or family history suggestive of a hereditary cancer syndrome 
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o Genetic testing results can be adequately interpreted  
o The results will aid in the diagnosis or impact medical management of the patient or at-
risk family members 
Testing criteria for HBOC are published by the National Comprehensive Cancer Network4. The 
testing criteria includes the following:  
o Individual from a family with a known deleterious BRCA1/2 mutation  
o Individual with a personal history of breast cancer (including IDC and DCIS) and 
one or more of the following: 
o Breast cancer diagnosed ≤ 45 years  
o Two breast primaries, the first breast cancer diagnosed ≤ 50 years  
o Breast cancer diagnosed ≤ 50 years with ≥ 1 close blood relative with 
breast cancer at any age or with a limited family history  
o Breast cancer diagnosed ≤ 60 years and is triple negative breast cancer  
o Breast cancer diagnosed at any age with ≥ 1 close blood relative with 
breast cancer diagnosed ≤ 50 years  
o Breast cancer diagnosed at any age with ≥ 2 close blood relatives with 
breast cancer diagnosed at any age  
o Breast cancer diagnosed at any age with ≥ 1 close blood relative with 
epithelial ovarian cancer  
o Breast cancer diagnosed at any age with ≥ 2 close blood relatives with 
pancreatic cancer or aggressive prostate cancer at any age  
o Breast cancer diagnosed at any age and ≥ 1 close male blood relative with 
breast cancer 
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o Breast cancer diagnosed at any age of an ethnic background associated 
with higher mutation frequency (eg, Ashkenazi Jewish).  
o Personal history of epithelial ovarian cancer  
o Personal history of male breast cancer  
o Personal history of pancreatic cancer or aggressive prostate cancer at any age with 
≥ 2 close blood relatives with breast and/or ovarian and/or pancreatic or 
aggressive prostate cancer at any age  
o Family history only  
o 1st or 2nd degree blood relative meeting any of the above criteria  
o 3rd degree relative with breast cancer and/or ovarian cancer with ≥ 2 close 
blood relatives with breast cancer (at least 1 diagnosed ≤ 50 years) and/or 
ovarian cancer  
1.2.5.2 Genetic Testing Methodologies  
The clinical methodologies for molecular genetic testing of BRCA1/2 include sequence analysis, 
deletion/duplication analysis, and targeted mutational analysis. Testing is performed using DNA 
extracted from a peripheral blood sample or buccal sample2. Until recently, the majority of genetic 
testing for BRCA1/2 was performed by Myriad Genetic Laboratories due to patent rights of the 
sequence analysis. In June 2013, the U.S. Supreme Court ruled that DNA fragments of the human 
genome are ineligible for patent rights54.  Sequence analysis is now offered by more than nine labs 
in the United States.  
Deletion/duplication analysis is available to identify large genomic rearrangement within 
BRCA1 and BRCA2 and is estimated to identify an additional 12% of mutations41; 55.  
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Targeted mutational analysis is available for detecting the three HBOC founder mutations 
of individuals of Ashkenazi Jewish ancestry2. Targeted 3-site analysis is estimated to detect 90% 
of mutations within this population. Site specific mutational analysis is also available to identify 
the presence of known familial mutations2.  
With the advancements in next generation sequencing, panels have allowed the evaluation 
of multiple genes associated with other hereditary breast and ovarian cancers syndromes52. This 
approach has been useful for patients and families that present with features of more than one 
hereditary cancer syndrome. This makes testing for multiple genes more efficient and cost 
effective. While some of the genes included in these panels are well-described, several lesser 
known genes are included, for which cancer risks and medical management recommendations for 
mutations carriers are unclear at this time.  
1.2.5.3 Genetic Testing Strategies and Results Interpretation  
To ensure the most informative results, genetic testing for BRCA1/2 is initiated for those with a 
personal history of breast and/or ovarian cancer whenever possible4. Comprehensive testing is 
indicated for the family member with the highest likelihood of carrying a BRCA1/2 mutation. If 
more than one family member is affected, individuals with the youngest age of diagnosis, those 
with bilateral breast cancer, multiple primaries, and ovarian cancer have the strongest likelihood 
of being carriers4. If no mutation is identified in the most appropriate person to test within the 
family, testing other family members is not necessary or useful, thus conserving healthcare 
resources. If a mutation is identified, it allows for site-specific mutational analysis for other family 
members, and test results are informative even for those family members who are unaffected.  
For individuals of Ashkenazi Jewish (AJ) descent, it is recommended that testing begin 
with targeted mutation analysis of the three specific founder mutations4. If no mutation is detected 
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with the 3-site mutation analysis and the individual meets NCCN criteria for HBOC, despite their 
Ashkenazi Jewish ancestry, follow up testing for comprehensive analysis is available. It is 
recommended that individuals within the AJ population be tested for all three AJ founder 
mutations, rather than site-specific testing for a known AJ mutation within their family4. This is 
due to the increased frequency of these mutations within the AJ population and the identification 
of two founder mutations within some AJ families.  
There are four possible test results from BRCA1/2 genetic testing4. A “true positive” result 
means that an individual is a carrier of a BRCA1/2 mutation, which increases the risk for HBOC-
related cancers. A “true negative” result means that an individual is not a carrier of a BRCA1/2 
mutation previously identified within the family. In the absence of a known family mutation, A 
“no mutation detected” result mean that an individual was not found to be a carrier of a BRCA1/2 
mutation and cancer risk is based on personal and family history. Lastly, a “variant of uncertain 
significance” (VUS), indicates identification of a subtle change within BRCA1/2 for which the risk 
of HBOC-related cancers is unknown.  
Disclosure of results should include personalized interpretation of results, including cancer 
risk assessment and identification of at risk family members48. This information should be 
conveyed for positive, negative, and inconclusive results.  
1.2.5.4 Benefits and Limitations of Genetic Testing  
ASCO recommends that genetic testing include pre-test counseling, including a discussion of 
possible benefits and limitations of testing53. The benefits of genetic testing for HBOC include the 
clarification of personalized cancer risks and risk management. Information about mutation status 
can aid in the making of informed decisions regarding medical management for both individuals 
with a personal history of cancer and those who do not. Another potential benefit of genetic testing 
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is the clarification of risk for other family members. Identification of a BRCA1/2 mutation in one 
family member enables other at-risk family members to determine whether or not they share the 
same cancer risks.  
Genetic testing for HBOC has limitations since only a small portion of these cancers will 
be due to an identifiable gene mutation and genetic testing is unable to identify all possible 
mutations. This means that a negative test result is most informative when there is a known 
mutation identified within a family. In the absence of a known family mutation, interpretation of 
a negative result may be limited, particularly when testing an unaffected individual. The possibility 
of identifying a VUS is approximately 2.9-7.8%56, depending upon the population tested. For those 
individuals, medical management decisions are based upon personal and family history. It is also 
possible that other genes are contributing to hereditary breast and ovarian cancer within a family. 
Other limitations of genetic testing include the inability for prevention and screening 
methodologies to detect all cancers at an early stage.   
Individuals are often concerned about the risk of confidentiality and the risk of genetic 
discrimination by insurance companies57. In 1996, the Health Insurance Portability and 
Accountability Act (HIPAA) was enacted, which provides the protection of medical information, 
including genetic information for individuals within group health insurance plans58. In 2008, the 
Genetic Information Nondiscrimination Act (GINA) was enacted, which protects patients from 
potential discrimination from employers and health insurance companies based on genetic testing 
information57. The law does not protect individuals from discrimination in the context of life 
insurance, disability, and long-term care insurance providers.  
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1.2.6 Psychosocial Issues Related to HBOC  
According to the National Society of Genetic Counselors’ recommendations for genetic testing, 
psychosocial assessment of the patient should be included in both the pre- and post-test genetic 
counseling process48. This includes identifying the patient’s motivation for genetic testing and 
assessing the patients understanding of information and testing process. Genetic testing may have 
a great impact on their medical management decisions, lifestyle, and relationships with others. 
 For individuals who have experienced an HBOC-related cancer, a positive test result can 
bring about a variety of emotions, both positive and negative59; 60. For some, a positive test result 
can provide an explanation for the cancer diagnosis. For others, a positive result may induce 
feelings of anxiousness, sadness, and fear related to additional cancer risks that are associated with 
having a BRCA1/2 mutation. In addition, feelings of guilt regarding passing a mutation to children 
may result.  
Approximately 20% of BRCA1/2 mutation carrier women experience high distress after 
receiving their genetic testing results59. However, distress symptoms, including anxiety, 
sleeplessness, and changes in mood, were often minimal, did not affect everyday life activities, 
and greatly resolved after one year59.  
Receiving a negative test result may bring similar emotions as a positive result. For most 
individuals, a negative test result is reassuring and brings relief from knowing they are not at a 
substantially increased risk for the development of HBOC-related cancers59. For others, a negative 
result can be associated with “survivor guilt”, especially if a mutation has been previously 
identified within a family, and other family members, including siblings, have inherited the 
mutation61.  
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1.3 RECONTACTING PATIENTS IN CANCER GENETICS 
1.3.1 Possible Situations for Recontact 
There are several situations in which recontact of patients by their genetics providers has been 
considered, including reclassification of “variant of uncertain significance” test results and 
availability of additional testing options.   
1.3.1.1 Variants of Uncertain Significance (VUS) 
As uptake of genetic services and the utilization of genomic sequencing increases, the frequency 
in the number of unreported gene changes, where the clinical significance is uncertain, will 
increase as well62. The reporting of these novel sequence variants to physicians, genetics providers, 
and patients must include a clinical interpretation based on the current data available at the time of 
testing. Family studies and gene expression studies may be useful to clarify new variants, and 
clinical laboratories often work with researchers to classify these new variants as either harmful or 
benign63. 
Because variants of uncertain significance are uncommon, knowledge of them is often 
restricted to a few laboratories, and they may not be published in the literature. Testing laboratories 
may be the most appropriate entity to modify the interpretation of a VUS. Therefore, testing 
laboratories should make an effort to contact physicians and/or ordering providers in the event that 
a VUS should be reclassified64.  Reclassification of a VUS may help dissipate any psychological 
distress while clarifying cancer risks and helping to define the most appropriate medical 
management services for an individual65. At the present time, genetics providers and patients who 
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receive VUS results should discuss a plan for recontact in the event that new information becomes 
available62.  
1.3.1.2 New Genetic Testing Methods  
Technical advances in genetic testing that include improved sensitivity of testing are relevant for 
patients who have undergone previous testing with a less sensitive test. For example, sequence 
analysis of BRCA1/2 has been available since 1996 and since that time a number of changes have 
occurred to the testing process. In August 2006, Myriad Genetics® introduced a new component 
to BRCA1/2 testing, called BART (BRACAnalysis Rearrangement Test®) which aimed to detect 
large genomic rearrangements in BRCA1/255. When BART® was first introduced, Myriad Genetics 
established specific testing criteria based on personal and family history, offering testing to 
individuals with a greater than 30% risk of carrying a BRCA1/2 mutation55. Current NCCN Criteria 
for HBOC recommends large rearrangement testing for all patients undergoing BRCA1/2 
sequencing, based on studies supporting the benefits of large rearrangement testing in individuals 
who do not have high pretest probabilities of carrying a mutations in BRCA1/24; 20. Currently, large 
rearrangement testing can be performed simultaneously with sequence analysis of BRCA1/255. 
Because large rearrangement testing was determined to be a useful test for all individuals 
undergoing BRCA1/2 sequencing, the question of recontact has been raised for those patients who 
had BRCA1/2 sequence analysis before the introduction of large rearrangement testing66.  
Until recently, only single gene tests were available for hereditary cancer syndromes. The 
introduction of next-generation sequencing has allowed for simultaneous testing of multiple 
hereditary cancer genes67. The main benefit of this approach is to carry out genetic testing in a cost 
effective manner for individuals whose personal and family histories are suspicious for more than 
one hereditary cancer syndrome. Testing for a panel of genes can lead to greater sensitivity for 
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assessing cancer risks compared to sequential genetic testing of individual genes and will be more 
cost effective. Improving risk assessment can aid clinicians in making more informed decisions 
about cancer prevention and screening by identifying individuals most likely to benefit from those 
interventions. In addition, cancer panel screening may detect mutations in genes that would not 
typically be considered for testing based on medical or cancer family history, thus allowing the 
ability to identify cancer risks that would not have previously been considered and for which 
management options can be developed. It’s unlikely that an individual will meet criteria to warrant 
genetic testing for all of the genes included in a panel. However, it is estimated that approximately 
30% of individuals with a mutation in a cancer predisposing gene will not have a family history 
significant enough to warrant testing due to incomplete penetrance, sex limited expression, or lack 
of personal/family history.67  Offering cancer gene panels to a wider population to allow the ability 
to assess risks in individuals who do not meet the standard high risk criteria for offering genetic 
testing has been suggested68.  
While there are many advantages to the utilization of multi-gene panels, there are still a 
number of challenges to recognize within the clinical setting. One challenge includes defining a 
target population to offer testing to in order to achieve the most appropriate use of resources. In 
addition, interpretation and communication of test results presents additional challenges68. This 
includes the possibility of multiple pathogenic mutations identified and the increased chance of 
identifying a variant of uncertain significance. Even with the identification of single pathogenic 
mutations within one gene, the ability to provide accurate cancer risks may be limited by the 
availability of such data.  For less common low penetrant variants, large prospective studies that 
provide lifetime risk estimates of associated cancers are lacking. Implications of positive test 
results are also complex, as they differ for each gene and mutation detected. Availability of risk 
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reduction, prevention, and treatment options may vary widely depending on which gene is 
involved, especially for the lesser known low penetrant genes. For lower penetrance genes that 
lack established management guidelines, the clinical implications are less clear.  
Over time, supporting evidence for cancer risks and management consensus will emerge 
as utilization of cancer gene panels increases and large-scale studies are coordinated. Just as 
individuals have elected to pursue large rearrangement testing after BRCA1/2 sequence analysis, 
patients who have previously tested negative for BRCA1/2 may also benefit from undergoing 
testing of other hereditary cancer genes.  
1.3.2 ACMG Policy Statement: “Duty to Recontact”  
Due to the evolving nature of genetic testing availability, the American College of Medical 
Genetics (ACMG) introduced a policy statement regarding the responsibilities of recontact when 
new genetic information arises5. The policy states that after an initial genetics consultation, the 
referring physician, the designated primary care physician, and the patient should receive a written 
summary of the recommendations made, including recommendations for the patient to contact the 
genetics providers upon new advances in genetic testing5. In a small percentage of cases, where 
the medical genetics provider provides an on-going service, it is the medical geneticist’s 
responsibility to provide clinical updates to those patients.  The policy also states that the patient 
should be properly counseled to share updates to their medical and family history with their 
primary care physician and/or genetics provider. This policy was established to identify whose 
responsibility it is to recontact patients, when the recontact should occur, and whether the patient 
is a responsible party in the process of obtaining new genetic information.  
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1.3.3 Primary Care Responsibilities  
The ACMG “Duty to Recontact” policy places the responsibility of keeping patients informed of 
genetic discoveries on the referring physician and/or the primary care physician, due to the 
continuous relationship they establish with their patients. Previous studies have observed several 
barriers that primary care physicians face regarding the delivery of genetic service information. 
Often times, primary care providers are overwhelmed in keeping up to date with advances in 
clinical genetics and genetic testing technologies. This includes a general lack of basic knowledge 
of genetics and lack of awareness of genetic services69.  
As previously stated, identification of individuals at high risk for hereditary cancer 
syndromes requires an adequate family history assessment and can influence genetic testing 
recommendations. Studies have shown that while primary care physicians do utilize family history 
information as the primary tool for referral, family history information tends to be under-collected 
in clinical practice70. Physicians may be less adequately trained to obtain or document a complete 
family history, which includes cancer type and ages of diagnosis. Age of diagnosis is frequently 
omitted from family history interview questions70. Family history information is often less accurate 
when the complexity of family history increases, such as an increasing number of cancer diagnoses 
within a family. Other studies have reported physicians’ lacking skill in constructing a three-
generation pedigree and interpreting cancer risks by pedigree analysis. Often times, lack of time 
spent with a patient is considered a barrier to the ability to collect such information. One 
observational study of 138 primary care physicians concluded that physicians spend less than two 
and a half minutes discussing family history information with patients69.  
Overall, physicians demonstrate insufficient knowledge of hereditary breast and ovarian 
cancer and other hereditary cancer syndromes, lacking the ability to distinguish low and high risk 
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patients71. Physicians also lacked basic knowledge of hereditary cancer syndromes, including 
inheritance patterns and cancer risks. While physicians were comfortable referring to genetics 
providers, they had less knowledge of their availability and the services which were provided. 
Limited knowledge of the genetic testing process, including methods and costs of testing has also 
been observed.  
1.3.4 Patient Responsibilities  
The ACMG “Duty to Recontact” policy also places a large role of responsibility upon the patient 
to seek new information regarding genetic discoveries. Patients obligations include the action of 
contacting their physician or provider at previously agreed to periods of time for new information, 
making reasonable effort to understand the nature and implications of new information, and 
making reasonable use of resources available to keep themselves informed72; 73. In addition, 
patients may request additional consultations for clarification of information or if genetic 
counseling is needed.  
1.3.5 Genetics Providers Responsibility  
Despite the current ACMG policy, genetics professionals have struggled with the notion of their 
own “duty to recontact”. This phrase refers to the ethical and/or legal obligations of genetics 
service providers to recontact former patients regarding advances in genetic testing services that 
may be relevant to them 74. There may be a continuing obligation to recontact the client when new 
information becomes available that would have an impact on that client’s decision making75. 
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There are several situations in which there may be an ethical obligation to recontact 
patients: 1) for an individual in whom a diagnosis is suspected, but not achieved, 2) when a more 
accurate diagnostic and/or prognostic test has been developed.  3) when new information may alter 
the prognosis or recurrence risk estimates74. 
Attitudes regarding a moral obligation to recontact patient has previously been assessed.  
A study by Fitzpatrick et al, 1999 administered surveys to 1,000 randomly selected members of 
the American Society of Human Genetics, who were primarily physician geneticists (41%), Ph.D. 
geneticists (30%), and genetic counselors (18%)74.  Respondents, overall, agreed that the 
responsibility for staying in contact with patients should be shared between all health professionals 
and patients. However, 46% of individuals agreed that recontacting patients should be the standard 
of care, while 43% answered that recontacting patients should not be the standard of care. This 
divide may be due to the consensus from genetics providers that recontact is ethically desirable in 
most cases; however, it is neither feasible nor practical76.     
1.3.6 Current Practice and Limitations of Recontact 
Currently, there are no practice guidelines or standards of care to follow for patient recontact, so 
many genetics providers are left to follow their best clinical judgment77. In all situations, genetics 
providers’ documentation should include a request to the patient to keep in touch, especially if 
their personal history or family history changes. A patient letter may also include statements about 
the potential future of genetic testing and availability of testing as technological advances arise63.  
Strategies of recontact have been suggested, including identifying a target population to 
recontact by means of chart reviewing or extracting information from a database66. Once a target 
population is identified, an effort to recontact those individuals through various methods may be 
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achieved (personalized letters, phone calls, or newsletters) depending on the population size and 
resources available. 
Some genetics providers have addressed their concerns regarding the limitations of 
recontact and have proposed methods for how to recontact patients successfully77. The use of an 
adequate clinical database that includes patient names, addresses, and genetic testing result may 
be essential for the ability to recontact patients. This information allows the ability to query 
appropriate individuals and readily perform a bulk mailing. The information presented to the 
patient must be presented in a clear, concise manner with as much information as possible about 
the new genetic test.  
Genetics providers who initiate recontact should be prepared to handle an influx of 
additional patients.  This would include availability of appointment times, in addition to regularly 
scheduled new patients. No matter how reliable the database, certain patients who should be 
notified may be missed, due to lack of current contact information, viability status, and human 
error of incorrect data entry. Addressing these issues can be very cumbersome and time 
consuming. While careful planning can reduce some of these issues, they will never be eliminated 
completely.  
1.3.7 Patient Preference for Recontact  
Limited information exists regarding patient expectations and preferences concerning recontact to 
provide updated information regarding advances in cancer genetics. Griffin et al., 2007, conducted 
a study to evaluate the preferences for recontact of colon cancer genetics patients previously seen 
by the Colon Cancer Risk Assessment Clinic at Johns Hopkins Hospital. The study included 
recontact of former patients with information about recent advances in colon cancer genetics, 
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including large rearrangement testing and the discovery of the MSH6 and MUTYH genes. Results 
of the study revealed that the majority of patients wanted an ongoing relationship with their 
genetics providers (63%), and preferred that contact be re-established by their genetics providers 
(65%). In addition, 51% of patients wanted to be contacted with information that was specifically 
relevant to their own personal medical history. Preferences for methods of recontact included 
personalized letter (51%), generalized letter (35%), and newsletter (14%). Only 1% of respondents 
believed that recontact should be initiated by their primary care provider. Respondents believed 
that the primary responsibility for updating patients belonged to the genetics providers, followed 
by their primary care physicians and gastroenterologists. Only 10% of respondents believed that 
the patient held primary responsibility for seeking updated information.  Studies evaluating 
expectations and preferences of patients tested for other cancer predisposing genes have not yet 
been completed. 
1.3.8 Patient’s Right Not to Know 
It must also be considered that patients have the right to not seek additional information regarding 
their genetic health78. Autonomy includes the right to decide whether or not to seek information, 
and therefore, the right to remain uninformed. By re-initiating recontact, it may be violating the 
patients’ right to privacy and “right not to know”78. When a patient is referred for a genetics 
consultation, he or she has the right to refuse the appointment. Approximately 10% of genetics 
patients do not appear for their scheduled appointments72. Nor can it be assumed that because a 
patient attended the initial genetics consultation that he or she would automatically wish to be 
recontacted with new information.  
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While informing patients of new information may allow for better medical management 
decisions, the possible negative impact of such recontact should be considered as well. This 
includes the impact it would have on the psychological and emotional state of the patient, in which 
recontact may arouse these emotions, which were previously laid to rest72 
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2.0  EXPERIMENTAL DESIGN AND METHODS  
2.1 QUESTIONNAIRES  
The questionnaires used for this study were created by members of the Cancer Genetics Program 
of the University of Pittsburgh Medical Center and reviewed by Francesmary Modugno, PhD, 
MPH of the University of Pittsburgh Department of Epidemiology. Questionnaires were approved 
for research purposes by the Institutional Review Board at the University of Pittsburgh, 
Pennsylvania. The “Evaluation of Patients’ Preferences for Recontact by Cancer Genetics 
Providers” survey (Appendix H) included 13 multi-tiered multiple choice and order ranking 
questions. The “Cancer Genetics Provider Attitudes Regarding Recontact” survey (Appendix E) 
included 13 multi-tiered multiple choice and short answer questions. Both surveys included the 
opportunity for participants to elaborate on their responses and include personal comments.   
Questions and data used for this study were extracted from the two questionnaires. The 
patient survey contained four sections: 1.) evaluation of primary care relationship, 2.) expectations 
for recontact, 3.) preferences for recontact by genetics providers, 4.) factors that influence decision 
making regarding additional genetic testing. The healthcare provider survey contained three 
sections: 1.) Personal background, 2.) Current practice of recontacting patients, 3.) Theoretical 
consideration for recontacting patients.  
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2.2 PARTICIPANTS  
A query was created with the UPMC Genetics Information System to identify patients tested for 
BRCA1/2 between the years 2007-2012. Throughout these years, a total of 2,771 patients were 
tested for BRCA1/2. Of the individuals tested, 19.88% tested positive for a BRCA1/2 mutation, 
2.60% received a VUS result, and 77.52% tested negative for a BRCA1/2 mutation (Table 3).  A 
random sample of 1000 patients was selected using the random sample function in Microsoft 
Excel®. A review the UPMC electronic medical records was performed to confirm vital status and 
current contact information for the selected participants. As illustrated in Table 4, the random 
sample contained a comparable proportion of BRCA1/2 positive, negative, and VUS results to the 
initial sample of patients.  
Table 3. Total Number of Patients Tested for BRCA1/2 Throughout 2007-2012 
 Years 
Total # 
patients Positive  % VUS  % Negative  % 
2007 282 48 17.02 11 3.90 223 79.08 
2008 466 123 26.39 10 2.15 333 71.46 
2009 483 106 21.95 11 2.28 366 75.78 
2010 515 91 17.67 10 1.94 414 80.39 
2011 489 102 20.86 10 2.04 377 77.10 
2012 536 81 15.11 20 3.73 435 81.16 
Total 2771 551  19.88 72 2.60  2148  77.52 
 
Table 4. Randomly Selected Patient Population 
Years 
Total # 
patients  Positive  % VUS % Negative  %  
2007-2012 1000 184 18.40 31 3.10 785 78.50 
 
Current members of the National Society of Genetic Counselors “Familial Cancer Risk 
Genetic Counseling” Special Interest Group were selected to participate in the healthcare provider 
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portion of the study. This special interest group (SIG) was created for individuals who provide 
genetic counseling and cancer risk assessment. As of January 2013, there were 490 members of 
the NSGC Cancer SIG.  
2.2.1 Recruitment  
Initially, the patient survey was distributed by mail to 500 randomly selected patients who were 
tested for BRCA1/2 throughout the years of 2007-2012.  To increase participation, the patient 
survey was distributed by mail to another 500 randomly selected patients. These individuals were 
patients tested for BRCA1/2 in more recent years, throughout the years of 2010-2012. Participants 
were given unlimited time to return surveys and a follow up phone call was given to participants 
who had not returned their survey after one month.  
The healthcare provider survey was distributed to the 490 members of the National Society 
of Genetic Counselors Cancer Special Interest Group via an electronic survey. Members were 
given a two-week follow-up notice and several follow up notices thereafter to increase 
participation.  
Informed consent, including a signed consent form (Appendix G) or consent waiver 
(Appendix C ) was obtained from participants prior to completion of the questionnaires. 
2.3 DATA CLEANING 
A data cleaning process was developed and performed on data from the surveys. The goal of data 
cleaning was to minimize making changes to or making assumptions about the data to preserve 
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the participants’ responses in order to avoid making any questions unreliable. If a Yes/No question 
was blank but information was entered in corresponding “If yes” question or if an answer was 
entered for the “If no” question, the blank Yes/No variable was changed to “Yes” or changed to 
“No”, respectively. Questions which were skipped or had comments written in stating a phrase 
similar to “Unsure” or “I can’t remember” were regarded as such. In addition, if a respondent wrote 
in an answer in an “Other reasons” box, and it was similar to an already available answer, then the 
response was changed to the multiple choice option. Questions which were answered improperly 
were discarded for those participants. These situations most commonly included improper ranking 
of responsibility for recontact and selecting more than one answer for questions that required only 
one response. In addition, the final section of the questionnaire asked participants to fill it out only 
if they had received a “No mutation detected” or a “Variant of Unknown Significance Detected” 
result from their previous BRCA1/2 testing. Answers were discarded for individuals who received 
a positive “Mutation Detected” result for BRCA1/2 and still completed this section. 
Because not all respondents answered every question, the total number of responses, 
represented by “n”, are provided for each question in the Results section.  
 
 
 
 
  
36 
2.4 DATA ANALYSIS 
After data was collected from both survey populations, statistical analyses were performed using 
the statistical software package SPSS Statistics 21® and Microsoft Excel® formulas. Qualitative 
and descriptive statistics were produced for selected study characteristics. Chi-square and Fisher’s 
exact tests were used to analyze and identify centralized themes within the data. A p-value of ≤ 
0.05 was considered statistically significant.  
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3.0  RESULTS 
3.1 SPECIFIC AIM 1: PATIENTS 
3.1.1 Response Rate  
In total, there were 254 complete surveys returned from 1000 randomly selected patients. The 
response rate for completion of the survey was 25.4%. An additional 18 surveys were discarded 
due to being undeliverable to the sender or for containing incomplete study documentation (lack 
of signed consent forms or survey). We can conclude that the responses of those who completed 
the survey are representative of the randomly selected patient population with 5.31% margin of 
error determined by the Krejcie and Morgan Table: “Determining Sample Size for a Given 
Population”79.  
3.1.2 Demographics  
Table 5 illustrates the characteristics of the participants by several categories including: gender, 
age, year of BRCA1/2 testing, and BRCA1/2 test results.  
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Table 5. Characteristics of Patients  
Gender Responses % 
Male 15 5.91 
Female 239 94.09 
Age Responses % 
18-24 1 0.39 
25-34 12 4.72 
35-44 41 16.14 
45-54 74 29.13 
55-64 81 31.89 
>65 45 17.72 
Year Responses % 
2007 12 4.72 
2008 20 7.87 
2009 27 10.63 
2010 79 31.10 
2011 52 20.47 
2012 64 25.20 
Result Responses % 
Negative 194 76.38 
Positive 49 19.29 
VUS 11 4.33 
 
Of the 254 individuals who responded, 94% were female and nearly 6% were male. The 
ages of the study participants were grouped and the groups ranged from 18 years to greater than 
65 years. The majority of participants were over the age of 45 years, which is consistent with the 
age range for the population of patients that are typically referred for BRCA1/2 testing. More 
responses were collected from individuals tested between 2010-2012, reflective of the larger 
proportion of patients selected from these years to participate in the study. Characteristics from 
patients who did not respond were similar, signifying there were no biasing demographic factors 
within the study population. 
Response rates for each year the patients received genetic testing and the response rate for 
each BRCA1/2 results group were analyzed separately (Tables 6 and 7). Response rates were 
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almost equally distributed, ranging from 20% to 34% for the five years that participants were 
selected from. Response rates were the highest (34.5%) among individuals who received a “variant 
of uncertain significance” result, and rates were similar between those who had received positive 
and negative results, at 26.6% and 24.7% respectively.  
Table 6. Patient Response Rate by Year 
Year  Reponses  Total % 
2007 12 47 25.53 
2008 20 78 25.64 
2009 27 79 34.17 
2010 79 274 28.83 
2011 52 249 20.88 
2012 64 273 23.44 
 Overall  254 1000 25.40 
 
Table 7. Patient Response Rate by BRCA1/2 Results 
 
 
 
3.1.3 Evaluation of Primary Care Physician and Specialist Relationship  
Of the 254 responses, 89.8% of patients reported seeing their primary care physician regularly. Of 
those individuals, 74.1% reported that they had shared their genetic test results with their PCP. 
Those who shared their genetic testing results with their PCP primarily (72.8%) believed that that 
their PCPs were knowledgeable regarding their genetic health. Whereas of the 22.8% of patients 
who did not share their genetic testing results with their PCP, only 26% believed that their 
providers were knowledgeable regarding their genetic health (Figure 2).  
 Responses  Total  % 
Positive  49 184 26.63 
Negative  194 785 24.71 
VUS  11 31 35.48 
Overall 254 1000 25.40 
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Figure 2. Sharing Genetic Test Results with PCP and Perceived PCP Knowledge 
There was statistical significance (p-value <0.0001) showing a relationship between those 
who thought their PCP was knowledgeable regarding their genetic test results and their decision 
to share test results with those providers (Table 8).  
Table 8. Sharing Genetic Test Results with PCP vs. Perceived PCP Knowledge by Patients 
   
Shared genetic test 
results  
    No  (%) Yes (%) 
PCP 
knowledgeable 
regarding genetic 
health 
n=210 
No 36 (17.1) 37 (17.6) 
Yes  14 (6.6) 123 (58.5) 
  p-value  <0.0001   
 
The same question was asked of the participants regarding their oncologist/breast 
specialist. In total, 79.9% reported seeing their specialists regularly. Of those individuals, 95.5% 
had shared their genetic testing results with their provider. Those who shared their genetic testing 
result with their specialist primarily believed (83.3%) that their provider was knowledgeable 
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regarding their genetic health. Of the 2.9% who did not share their results with their specialist, 
88.3% believed that their providers were knowledgeable regarding their results.  
In addition, there was no statistical significance showing a relationship between those who 
thought that their specialist was knowledgeable regarding their genetic test results and their 
decision to share test results with those providers. Tables illustrating these variables are located in 
Table 24 and Table 25 of Appendix I.  
3.1.4 Expectations for Recontact  
The survey asked patients to determine whose primary responsibility it is to keep patients informed 
regarding new genetic discoveries by ranking the following: patient, primary care provider (PCP), 
specialist, and genetics provider (Table 9). Forty-eight percent responded that their genetics 
providers held the most responsibility, while 38.6% ranked their specialist as having the most 
responsibility. Only 7.7% of patients found themselves the most responsible, while patients found 
their PCP least responsible (5.1%). 
Table 9. Primary Responsibility for Recontact According to Patients 
n=254 Responses % 
Patient  15 7.73 
PCP 10 5.15 
Specialist 75 38.66 
Genetics provider 94 48.45 
 
Patients’ expectations for recontact by their providers was compared with their responses 
regarding whether they shared their genetic testing results with their other providers and their 
perceived knowledge of the information. There were no differences observed between individuals 
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who believed their PCP or providers were or were not knowledgeable regarding their genetic 
health and which party they felt held the most responsibility for recontact (Table 26, Appendix I).  
In addition, patients were asked to recall, at the time of their initial genetics consultation, 
whether their genetic counselor had suggested recontact if changes occurred with their personal or 
family’s cancer history. Of the 250 patients who responded, 135 (54%) responded that they did 
not recall their genetic counselor’s recommendation to recontact them, 89 (35.6%) did recall this 
information, and 26 (10.4%) were uncertain (Table 10). Responses from patients tested between 
2007-2009 and patients tested between 2010-2012 was significantly different (p-value=0.05), 
suggesting that the patient’s ability to recall this information was influenced by the time elapsed 
since their genetic testing (Table 11).  
    Table 10. Recall to Recontact According to Patients  
n=250  Responses % 
No 135 54.00 
Yes 89 35.60 
Unsure 26 10.40 
 
                                    Table 11. Recall to Recontact vs. Year of Testing 
  Recall P-value 
  No Yes Unsure  
0.05 2007-2009 37(63%) 13(22%) 9(15%) 
2010-2012 98(51%) 76(39%) 20(10%) 
3.1.5 Preferences Regarding Recontact  
The survey also examined patients’ preferences for recontact including how often recontact should 
be initiated and by what method. Of the 250 individuals who responded, 76 (30%), indicated that 
recontact should be established regularly even if no new discoveries were made during that 
timeframe. The majority of those individuals (76.6%) indicated that recontact should be 
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established annually (Table 13). Forty-eight percent of individuals indicated that recontact should 
be established when the new information that became available was pertinent to the patient (Table 
12). Personalized letters to only appropriate patients was the preferred method of recontact by 66% 
of individuals (Table 14) and 66% believed that specific information and how it pertained to the 
patient should be included in the information received by the patient upon recontact (Table 15).  
Table 12. Patient Preferences for Recontact: When 
n=250 Responses % 
Regularly, even if no new discoveries are made 76 30.04 
When any new discoveries are made 48 18.97 
When new discoveries are made that directly pertain to the patient 123 48.62 
Unsure 3 1.19 
 
 
Table 13. Patient Preferences for Recontact: How Often 
n=76 Responses % 
> 1x/yr 8 10.53 
Annually  56 73.68 
Every 2-4y 5 6.58 
Every 5y 3 3.95 
Null 4 5.26 
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Table 14. Patient Preferences for Recontact: Method 
n=250 Responses % 
Generalized letter to all patients 27 10.80 
Telephone 17 6.80 
Media release 0 0.00 
Email 22 8.80 
Personalized letter to only appropriate patients 165 66.00 
Newsletter 3 1.20 
Continually updated website 1 0.40 
Did not answer properly 15 6.00 
 
Table 15. Patient Preferences for Recontact: Information Included in Recontact 
n=250 Responses % 
New information is available; ask patient to contact 
genetics if interested in more information 28 11.20 
New information is available; identify resource 
where more information is available 30 12.00 
Generally what new information has been identified 19 7.60 
Specifically what new information has been 
identified and how it pertains to specific patient 165 66.00 
Did not answer    8 3.20 
 
Patients were also asked whether it should be established at a patient’s first genetics 
consultation, whether he/she would like to be recontacted in the future if new information becomes 
available in the future. The majority of patients (96.8%) responded that this method should be 
practiced (Table 16).  
Table 16. Patient Preferences for Recontact Contract at First Consultation 
n=250 Responses % 
No 6 2.4 
Yes 242 96.8 
Unsure 2 0.8 
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In addition, patients were asked that if an individual answered “no” to be being recontacted 
at the initiation consult, were there any circumstances in which a provider should recontact the 
patient anyway. Of the 250 patients who responded, 29 (11.6%) patients indicated that there were 
no circumstances in which the genetics provider should recontact the patient. One hundred and 
ninety-seven patients (78.8%) indicated that there were certain circumstances which indicated a 
reason for recontact anyway, and 24 patients (9.6%) were uncertain or chose not to respond to the 
question. Of the individuals who indicated “yes”, the majority believed that recontact should be 
initiated when new information was specific to the patients’ health, medical management or 
treatment, or changed their risk of developing cancer (Figure 3). “Other” responses in favor of 
recontact included the ability to give patients a “second chance” for recontact, as their initial 
decision to not be recontacted may have been influenced by the overwhelming experience from 
their initial consultation.   
 
Figure 3. Circumstances for Desired Recontact by Patients 
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Other preferences regarding recontact included whether patients’ interests in being 
recontacted would change if that meant an additional consultation with their genetics provider. Of 
the 253 individuals who indicated that genetics providers should recontact patients, 209 (83.6%) 
thought that an additional consultation would not affect their interest in being recontacted, 36 
(14.4%) said that it would affect their interested, and 5 (2.0%) chose not to respond (Table 17).  
Table 17. Patient Interest for Recontact Changed when Additional Genetics Consultation is Required 
n=250  Responses % 
Yes  36 14.40 
No 209 83.60 
Did not 
answer 5 2.00 
 
Patients were also provided with a list of conditions for recontact and were asked under 
which conditions they would want to be recontact by their genetics provider. Figure 4 outlines the 
responses. Overall, individuals believed that recontact was useful to learn about new information 
relevant to cancer risk for themselves and family members as well as information about cancer 
screening. Individuals believed that recontact was less useful to develop a relationship with their 
genetics providers or to receive ongoing support.   
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Figure 4. Reasons for Recontact According to Patients 
3.1.6 Financial Factors that Influence Decision Making  
Overall, 205 participants had previously received either a negative or VUS test result. Of those 
individuals, 174 (84.8%) said that they would be likely to pursue additional testing if they were 
told that new genetic testing were available (Table 18). Nearly 86% of individuals with a negative 
BRCA test result claimed they would be interested, while 63.6% of individuals with VUS test result 
claimed they would be interested in additional testing. Of the 174 individuals who said they would 
be interested in additional testing, the majority (80-92%) felt comfortable pursuing testing if tested 
were offered free of charge by either a research or clinical basis or if their insurance company 
would cover the cost of the test (Table 19). One hundred and twenty-four individuals indicated 
that they would be willing to pursue additional testing by paying out of pocket, as long as costs 
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were within reason (Table 20). Of this group, nearly 85% of individuals claimed that a reasonable 
cost for additional testing would be less than $499. Only 9.6% of individuals were willing to pay 
out of pocket for additional testing, regardless of cost.  
Table 18. Interest in Additional Genetic Testing by BRCA Negative and VUS Patients 
  
Would be interested in pursuing additional testing  
Total Yes  % No  % Unsure % 
Neg 194 167 86.08 23 11.86 4 2.06 
VUS 11 7 63.64 2 18.18 2 18.18 
Total 205 174 84.88 25 12.20 6 2.93 
 
Table 19. Financial Factors for Additional Genetic Testing for BRCA Negative and VUS Patients 
n=174 No % Yes % Unsure % 
Provided free of charge through 
research  5 2.87 156 89.66 13 7.47 
Provided free of charge , but 
not through a research study  12 6.90 140 80.46 22 12.64 
If my insurance would cover the 
cost of testing  4 2.30 161 92.53 9 5.17 
 
Table 20. Reasonable Cost of Additional Genetic Testing According to BRCA Negative and VUS Patients 
Reasonable cost (n=124) Response % 
<100 53 42.74 
100-499 52 41.94 
500-999 10 8.06 
>1000 5 4.03 
Unsure 4 3.23 
Regardless of cost (n=124) Response % 
No 81 65.32 
Yes 12 9.68 
Unsure 31 25.00 
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3.1.7 Responses based on BRCA test results  
Each question was evaluated comparing individuals with BRCA positive, negative, and VUS 
results. This was done by comparing responses using Fisher’s exact test. Though responses varied 
by each results group, there were no statistically significant differences between the three groups. 
These comparisons and corresponding p-values can be found in Tables 27-35 of Appendix I.  
3.2 SPECIFIC AIM 2: CANCER GENETICS PROVIDERS 
3.2.1 Response Rate  
In total, there were 216 responses collected from the estimated 490 members of the NSGC Cancer 
Special Interest Group. Of the 216 responses, 3 surveys were discarded for incomplete survey 
responses. The response rate for the survey was 43.5%. We can conclude that the responses of 
those who completed the survey are representative of the randomly selected patient population 
with 5.05% margin of error determined by the Krejcie and Morgan Table: “Determining Sample 
Size for a Given Population”79. 
3.2.2 Demographics 
Table 21 illustrates the characteristics of the participants by several categories including: 
profession title, action of regularly providing cancer risk assessment in their job, type of work 
setting, and length of time spent providing cancer risk assessment.  
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Table 21. Characteristics of Healthcare Providers  
Profession Number of Responses % 
Genetic Counselor  210 98.59 
Geneticist  0 0.00 
Physician   0 0.00 
Physician Assistant  0 0.00 
Nurse  0 0.00 
Other  3 1.41 
Regularly Provide Cancer Risk 
Assessment  Number of Responses  % 
No 6 2.82 
Yes  206 96.71 
Other  1 0.47 
Work Setting  Number of Responses  % 
Independently  75 35.21 
Within formal genetics 
department  136 63.85 
Other  2 0.94 
Length Providing Cancer Risk 
Assessment Number of Responses  % 
<1y 30 14.08 
2-4y 59 27.70 
5-9y 58 27.23 
>10y 59 27.70 
Other  7 3.29 
 
Nearly all of the participants who completed the survey were genetic counselors (98.6%). 
Of the three respondents who chose “other”, two reported to be research assistants and one reported 
to be a genetic counseling intern. In addition, 96.7% responded that they regularly provide cancer 
risk assessment and 63.9% reported working within a formal genetics department. Number of years 
providing cancer risk assessment was divided in ranges. There was almost equal distribution, 
between these time frames. Demographic information for non-respondents was not available for 
this study sample.  
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3.2.3 Resources  
Respondents were asked to rate the following characteristics that describe the setting in which they 
provide cancer risk assessment (Figure 5). The majority of respondents either agreed or strongly 
agreed that they were provided with sufficient support staff (53%), financial support (60%), and 
sufficient database use (50%) within their work setting. Approximately one-third of respondents 
either disagreed or strongly disagreed that they were provided with these resources. Respondents 
were also able to select “neither agree or disagree” or chose not to respond.  
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Figure 5. Availability of Sufficient Resources According to Genetics Providers  
3.2.4 Current Practice of Recontact  
Overall, 67% of respondents had said that they have recontacted patients for the purpose of offering 
additional genetic testing (Figure 6). In addition, the study revealed that only 18.3% of respondents 
had established formal systems of recontact for clinical purposes (Figure 6). Similar responses 
were observed for research purposes. Methods of recontact collected from the comments section 
of the survey included the use of generalized information sent to all patients via a newsletter format 
(mail or email) or information published on a departmental website. Other genetics providers used 
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a database to set reminders for specific patients whom they categorized as high risk and would 
benefit from additional testing. Other providers used a database to track which patients showed 
interest in additional testing from their initial consultations. Other individuals commented that 
their genetics division had collectively made decisions about pertinent groups of patients to 
recontact, either queried a database or did a chart review to identify eligible patients, and then 
contacted those patients via phone calls or personalized letters.  
 
Figure 6. Current Practice of Recontact by Genetics Providers  
When comparing responses from providers who have recontacted patients to those who 
have not, the level of support for resources was evaluated. There was a statistically significant 
difference in the practice of recontacting patients between those who indicated having adequate 
resources, including staff, monetary support, and a sufficient database (Table 22). Providers who 
reported having sufficient resources were more likely to recontact than those who did not report 
sufficient resources. This indicates a significant influence these resources have on the practice of 
patient recontact.   
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Table 22. Genetics Providers Resources Influence on Recontact 
   Recontact  (%)   
    No Yes  P-value  
Staff 
n=203 
Disagree 30 (14.7) 47 (23.1) 
0.04 Neither Agree or Disagree 6 (29.5) 11 (5.4) 
Agree 24 (11.8) 85 (41.8) 
Monetary 
n=202 
Disagree 16 (7.9) 28 (13.8) 
0.005 Neither Agree or Disagree 16 (7.9) 16 (7.9) 
Agree 28 (13.8) 98 (48.5) 
Database 
n=203  
Disagree 22 (10.8) 44 (21.6) 
0.0124 Neither Agree or Disagree 16 (7.8) 18 (8.8) 
Agree 22 (10.8) 81 (39.9) 
 
 The same comparison was made regarding the degree of resources and provider’s 
establishment of a formal system of recontact. The only statistically significant difference in 
having a formal system of recontact was for those who indicated having a sufficient database. 
Genetics providers who reported not having sufficient database access were less likely to recontact 
former patients than those who did report having a sufficient database.  Degree of staff and 
monetary support did not influence the ability to have a formal system of recontact (Table 23). 
Table 23. Genetics Providers Resources Influence on Formal System of Recontact 
  Formal System (%)  
  No Yes  P-value  
Staff 
n=203 
Disagree 66 (32.5) 10 (4.9) 
0.1229 Neither Agree or Disagree 14 (6.8) 2 (0.9) 
Agree 80 (39.4) 26 (12.8) 
Monetary 
n=202 
Disagree 39 (19.3) 8 (3.9) 
0.2426 Neither 29 (14.3) 3 (1.4) 
Agree 95 (47.0)  27 (13.3) 
Database 
n=203  
Disagree 59 (29.0) 6 (2.9) 
0.006 Neither 29 (14.2) 4 (1.9) 
Agree 72 (35.4) 28 (13.7) 
 
Of the 213 respondents, 84% reported that they routinely direct patients to recontact their 
genetics providers for new information in the future (Figure 7). Approximately 9.4% reported that 
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they do not routinely direct patients to recontact them, while 6.6% chose not to respond to the 
question. Many individuals commented that this recommendation was conveyed in a letter to the 
patient, including the ability to recontact their genetics providers on a specific time line (annual, 
every 1-3 years), when there were changes noted within the family history, or when they heard 
about new information through the news or media. Others commented that they convey this 
information in person during a patient’s appointment. Some providers allowed the option for 
patients to schedule an annual appointment or the option to receive a reminder card in the mail. 
Some individuals commented on the lack of interest in patients to follow through with the 
recommendation and often times they are better at remembering to recommend this when the 
patient shows more interest or when the family history is high risk.  
 
           Figure 7. Genetics Provider Routine Request for Patients Recontact 
3.2.5 Theoretical Considerations of Recontact  
Participants were asked to describe how much of an ethical duty genetics providers have to 
recontact former patients regarding new advances in genetics (Figure 8).  Nearly 16% of genetics 
providers responded that they held no duty to recontact former patients, while 55.8% believed that 
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there was some duty to do so. Approximately 8% of respondents believed that there was a high 
degree of duty, while 14.5% were uncertain and 5.6% chose not to answer.  Participants were also 
asked to rate how much responsibility patients have to keep in touch with their genetics providers 
to learn more information regarding advances in genetics. The majority of participants, 63.8%, 
agreed that there was a high degree of responsibility for the patient to seek out the new information. 
Less believed that there were either no responsibility or some responsibility of patients, 1.4% and 
27.7%, respectively. Less than 2% were uncertain and 5% of respondents chose not to respond. 
Respondents commented that patient responsibility depended on the patient’s personal interest and 
motivation for genetic testing and also the patient’s need for genetic testing (high vs. low risk). 
Some genetics providers commented that they understood why patients would entrust a genetic 
counselor to hold the responsibility of recontact due to the intricacies of genetic testing 
information. Others commented about the burden felt by patients to recontact their provider 
multiple times over the course of years, possibly feeling embarrassed if no new information is 
available or feeling distress of the reminder that there is no known genetic cause.  
Overall, there was no statistical difference for providers to recommend routine patient 
recontact between genetics providers who believed that patients had a higher responsibility to 
recontact than those who had less responsibility to recontact (Table 36, Appendix I)  
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Figure 8. Genetics Providers Attitudes Regarding Responsibility for Recontact by Patients and 
Genetics Providers 
Genetics providers were also asked whether recontacting patients about clinical testing 
advances should be the standard of care practice and whether formal guidelines should be 
established for the purpose of recontacting patients (Figure 9). Overall, 19.2% of respondents 
believed that recontact should be the standard of care, while 70.4% did not. For this question, 
10.3% of participants chose not to respond. Comments from individuals who answered “yes” 
included beliefs that the notion was impractical due to lack of resources and infrastructure to do 
so. Comments from those who answered “no” aligned with belief of little duty to do so. 
Overall, 55.9% of respondents believed that formal guidelines should be established, while 
37.1% did not. For this question, 7% of participants chose not to respond. Comments from those 
who answered “yes”, included beliefs that formal guidelines would be helpful from a liability 
aspect, in which minimal responsibilities for recontact should be outlined, including who should 
be recontacted and what information should be conveyed to those individuals upon recontact. 
Others commented that guidelines would be useful, due to inconsistency in current practices. 
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Formal guidelines for recontact would be most useful if standards allowed flexibility in methods 
of recontact rather than mandated methods, and included strategies and suggestions for how to 
implement databases to quickly identify patients to recontact. Some respondents who answered 
“no” stated that ACMG policy guidelines were sufficient in outlining responsibilities and others 
stated that guidelines would quickly become unusable due to the rapid changes in technology.   
 
Figure 9. Genetics Providers Attitudes Regarding Recontact as Standard of Care and Desire for 
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4.0  DISCUSSION 
This study was designed to determine patients’ expectations and preferences for recontact by their 
genetics providers regarding new genetic tests that may become available. In addition, this study 
was designed to determine the utilization of recontact by genetics providers and survey the current 
methods used to do so. Implications of the study findings will aid in the development of 
recontacting strategies, as the availability of new genetic testing technologies expands. In addition, 
results may be useful in clarifying patient expectations for recontact to achieve better 
communication with patients regarding this process.   
4.1 SPECIFIC AIM 1: PATIENTS   
The first aim of the study was to identify patients’ current relationships with their primary care 
providers and specialists, identify patient expectations and preferences for recontact, and observe 
factors that may influence decisions to undergo additional genetic testing.  
4.1.1 Provider Relationships  
The study determined that patients were more likely to share their genetic testing results with their 
specialists than their primary care physicians. This observation may be biased due to the fact that 
the majority of individuals tested for BRCA1/2 at the site where the study was performed are 
referred by a specialist, most commonly a gynecologist or oncologist. After a genetic counseling 
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appointment, a consult letter is sent to the referring physician, which is less likely to be the patients’ 
PCP. Patients may also request that other physicians, including their PCP (if not the referring 
physician) be notified and have the option to discuss genetic testing results in person with their 
other providers.  Therefore, patients may have had different interpretations of “sharing genetic test 
results”, since this may have occurred through several methods of communication, either in person 
or through a consult letter via a genetics provider.  
The study observed that patients who did not share their genetic testing results with their 
PCP were more likely to indicate that they did not believe their PCP was knowledgeable regarding 
their genetic health. Almost all of the patients had shared their genetic test results with a specialist. 
Therefore, there was no correlation observed between individuals who did not share their genetic 
test results with a specialist and their perceived knowledge of genetic information. 
Notably, of 183 participants who reported having contact with both their PCP and 
specialist, only 3 did not share their genetic testing results with either their specialist or PCP and 
only 4 of 183 believed that neither their PCP nor specialist were knowledgeable. Therefore, the 
inability for patients to share results with a provider that they believed was knowledgeable would 
not impact a significant number of patients. While previous studies have proposed that healthcare 
providers have limited genetic knowledge, the data from this study suggests that participants 
believe their physician are informed and share their genetic testing results with them, signifying 
that PCP knowledge will not act as a barrier for disclosure as suggested by the ACMG policy to 
recontact. It may be that systems of recontact, through a genetics provider, could be most beneficial 
for patients who do not believe that their primary care physicians or specialists are knowledgeable 
of genetic information.  
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4.1.2 Expectations for Recontact  
Overall, patients held their genetics providers responsible for providing them with updates, 
regardless of whether they believed their other healthcare providers were knowledgeable regarding 
their genetic testing results. There are several possibilities for this observation. Patients may hold 
their genetics provider to a higher standard than their other providers and themselves because as a 
provider who specializes in genetics, they expect those individuals to have the most expertise and 
knowledge regarding the topic. Because of this, patients have respect and are more confident in 
the information received from the genetics providers. Another reason could be the lack of 
communication established between the genetics provider and the patient regarding the process of 
receiving new information. At the cancer genetics program where the study was held, almost all 
patients seen between 2007 and 2012 were directed to recontact their genetics providers if changes 
occur within the cancer family history that may change the assessment of the family’s risk. Specific 
statements requesting periodic recontact have been made in patient and physician correspondence 
since 2010 due to the evolution of genetic testing capabilities and the possible availability of new 
testing that could be of benefit to the patient and their family. The discrepancy in responsibility 
may then be due to patients not understanding the importance of this recommendation or due to 
the patient’s inability to recall the recommendation, which was reported by 35% of patients in this 
study.  
 The proportion of patients in this study who believed that their specialists were most 
responsible for recontact was higher than expected when compared to responses in a similar study 
conducted with colon cancer patients. Griffin et al., 2007 surveyed 851 patients seen at the Colon 
Cancer Risk Assessment Clinic at Johns Hopkins Hospital to evaluate patients’ expectations for 
recontact by their genetics providers.  The study observed that the primary responsibility for 
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updating patients belonged to the genetics provider (62-67% of patients), followed by PCP (19-
22%), then GI specialist (15-22%), and lastly the patient themselves (10%). The current study 
observed that only 48.4% of patients believed their genetics providers were most responsible, 
followed by their specialists (38.6%), then the patient themselves (7.7%), and last their PCP 
(5.1%). The new data suggests a more even divide in responsibility between genetics providers 
and specialists, less responsibility held by PCPs and an almost equal amount of responsibility held 
by patients themselves. Differences in these proportions may be due to variations in genetic 
counseling techniques between the two genetics programs and specific recommendations given 
about recontact. Alternatively, the observed differences may be due to differences in relationships 
between varying specialists (GI specialist vs. breast specialist), or gender (more males participated 
in colon cancer cohort).  
Interestingly, only 5.1% of patients believed that their PCP was most responsible, yet the 
majority of respondents believed that their PCPs were knowledgeable regarding their genetic 
testing results. It is possible that knowledge of genetic health influences the perceptions of who 
holds more responsibility in recontacting patients when comparing all parties involved (genetics 
provider, specialist, PCP, and patient). However, when comparing a primary care physician to a 
specialist, the distinction maybe made by other factors, perhaps personal relationship with a 
specific provider, disease specific knowledge of a provider, and overall time spent with a provider 
(cancer patients may spend overall more time with an oncologist vs. PCP).  
4.1.3 Preferences for Recontact  
Patients’ preferences for recontact were also compared to the Johns Hopkins study. This study 
found similar results to the colon cancer patient population, in that the majority of patients 
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preferred personalized letters sent to only appropriate patients and that the information directed to 
those patients should be specific to what new information exists, particularly pertaining to the 
patient. The majority of respondents desired to be recontacted only when new information was 
discovered that pertained directly to them.  
In addition, both the current study and the colon cancer study showed that the majority of 
individuals thought that patients should be asked at the initial consultation whether they wished to 
be recontacted (96.8% and 92% respectively). In both studies, a large proportion of patients (78.8% 
and 47%) indicated that there were specific situations in which a patient should be recontacted 
regardless of whether they requested not to be recontacted. While one strategy to reduce liability 
issues is to recognize which patients would want to be recontacted, it may be problematic that 
some patients believe it is appropriate to disregard this contract under certain circumstances. There 
is subjectivity in determining which circumstances would be “significant enough” for recontacting 
patients who initially decline which also leads to the possibility of violating patients’ preferences 
and their right not to be recontacted.   
The two studies also showed similar trends in reasons patients wished to be recontacted. 
More popular responses were for patients to be recontacted to receive new information regarding 
personal cancer risks and cancer risks to family members, information on cancer screening, and 
other information that may impact the overall health of the patient. Less common reasons for 
recontact included to develop a relationship with the genetics provider, reinforce decisions made 
during initial genetics consultation, and receive ongoing support.  
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4.1.4 Factors Influencing Decision Making  
While considering patients preferences for recontact, cost of additional testing could be a key 
factor in the success of recontact and uptake of additional testing. Of the 205 participants with a 
VUS or negative BRCA result, the majority indicated an interest in undergoing additional testing 
if the option were available. Response rates were similar between the individuals who responded 
in this study compared to those within the colon cancer study. In both studies, patients were 
interested in additional testing if it were free through research or non-research based approaches. 
Approximately 71% indicated that they would be willing to pursue additional testing by paying 
out of pocket as long as costs were reasonable, and the majority indicated that reasonable costs 
would be less than $499. Responses did not take into account individuals with “true negative” test 
results, meaning that a family mutation had already been identified and no additional testing would 
be indicated. Therefore, the proportion of patients interested in additional testing may be lower if 
those individuals been taken out of the analysis. 
4.1.5 Differences in Responses  
Differences in expectations and preferences for recontact between individuals who have received 
positive, negative, and inconclusive BRCA1/2 test results were not observed in this study. The 
main limitation to this observation was the small proportion of respondents with VUS and positive 
test results. Further assessment is necessary to draw any further conclusions.  
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4.2 SPECIFIC AIM 2: CANCER GENETICS PROVIDERS 
The second aim of this study was to determine current practices and methods of recontacting 
patients held by genetic healthcare providers for the purpose of additional genetic testing 
opportunities. In addition, the study aimed to revisit the degree of responsibility felt by genetics 
providers regarding recontact of patients. 
4.2.1 Current Practice of Recontact  
This study revealed that 67% of genetics providers have recontacted patients for the purpose of 
offering additional genetic testing and that 18% had established formal systems of recontact. The 
most recent study to determine practices of recontact was a study conducted in 1999 by Fitzpatrick 
et al. in which members of the American Society of Human Genetics were surveyed74. In that 
study, 61% reported that they had recontacted a patient regarding research advances in genetic 
testing. The previous study also reported that 13% of providers had developed formal systems of 
recontact for the specific purpose of recontacting patients. This suggests that over time, the rate of 
recontact has increased with the increase in opportunities for recontact (BART, additional testing). 
One could argue that this increase is not very dramatic for the degree of technological advances 
that have developed in interim of 15 years, possibly reflecting the barriers faced when recontacting 
patients.  
Many of the barriers faced by genetics providers include limited resources. It is not 
surprising how much of an impact these types of resources have on the ability to recontact patients 
and this study supports that having sufficient staff, finances and database all impact a genetics 
providers’ action to recontact patients. It is interesting that the only resource having a significant 
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influence on the ability to have a formalized system of recontact is a sufficient database. This study 
observed that formalized systems of recontact are less impacted by monetary support and staff, 
indicating the valuable role databases play in the process of recontacting patients and the value 
placed on recontact by the genetics providers. It is possible, in addition, that limited finances 
impacts the ability to invest in a sufficient database, while limited staff may also influence the 
ability to maintain and utilize database information. The comparison study by Fitzpatrick et al. did 
not inquire about resources available to those genetics providers; however, it is reasonable to 
suggest that resources provided to genetics programs may not have increased dramatically over 
the years, therefore contributing to the inability to invest in proper database systems and hence, a  
slow increased rate of recontact by providers. 
4.2.2 Theoretical Considerations  
The degree of ethical duty to recontact patients is consistent with the previous ASHG study, 
indicating that genetics providers believe there is “some degree of duty” to keep patients informed 
about technological advances. Genetics providers in the ASHG study also believed that the degree 
of responsibility was higher among patients than among the genetics providers themselves. This 
is consistent with the results of the current study, in which 63% of providers believed that patients 
had a high degree of responsibility for recontact, while only 8% of providers believed that genetics 
providers themselves had a high degree of responsibility for recontact.  
This study observed that only 19.2% of genetics providers believed that recontacting 
patients should be the standard of care practice, while 70.4% did not. When the same question was 
asked in the 1999 ASHG survey, respondents showed less of a consensus: 43% believed that it 
should be a standard of care while 42% did not. Comments regarding standard of care practice 
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were similar between the two studies. Those who were in support of the decision indicated that it 
would only be feasible under certain circumstances, including those with sufficient 
assistance/resources. Those who indicated “no”, commented on similar limitations. This change 
in consensus overall, may be due to the experiences of recontact over time, noting first-hand the 
barriers to recontact and the inability to improve them throughout the years. Furthermore, the 
change in consensus may also be related to the degree of change that has occurred with regard to 
genetic testing in recent years and the amount of time and resources that would be required to 
frequently recontact an ever growing patient population.  
In the current study, 55.9% of respondents indicated that formal guidelines should be 
established for recontact, with an overall trend that guidelines should include strategies for 
recontact. Previously, it has been observed that explicit guidelines do improve clinical practice, 
especially if the strategy developed is internal to the specialty80.  
4.2.2.1 Benefits and Limitations of Recontact  
This study observed several themes related to the perceived benefits and limitations of recontact.  
Comments regarding perceived benefits included providing improving quality of care for patients 
and the possibility of providing them with information that would reduce their uncertainty 
regarding medical management.  
 Comments regarding perceived limitations included the possibility of introducing more 
anxiety and stress for a patient through recontact and that information provided may create 
confusion for a patient. Other concerns were regarding privacy and patient autonomy. From a 
genetics provider perspective, limitations of recontact include limited time and staff, cost of 
information storage and retrieval, and lack of updated contact information for patients.  
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Some genetics providers believed that recontacting patients would introduce liability issues, 
especially in instances where patients could not be reached due to outdated contact information or 
potentially create unequal opportunities for additional testing based on which patients were 
selected to recontact.  
4.2.3 Differences in Expectations  
The two parts of the study indicate that patients assign a higher degree of duty to their genetics 
providers than genetics providers assign to themselves. This misalignment in expectations for 
recontact can create several areas of conflict. First, this situation can compromise the relationship 
between genetics providers and their patients resulting in dissatisfaction with their care. Second, 
the misalignment in expectations creates a potential for litigation, in which patients may be 
motivated by their unmet expectations for healthcare services.  
Strategies to improve unmet expectations may include ways of increasing patients’ 
awareness and responsibility for recontact. As shown by this study, the majority of patients do not 
recall being directed to contact their providers if there are changes to their personal or cancer 
family history. Mechanisms to help improve recall of this information may be useful. This may 
include altering delivery of this information and highlighting the importance of recontact. During 
a consultation, a patient may understand this recommendation, but also assume that a genetics 
provider may contact them with new information. Perhaps, a more comprehensive conversation 
regarding current recontact guidelines and the inability of a genetics provider to provide recontact 
services to all patients is worthwhile. A discussion on the topic of recontact during results 
disclosure, as well all its inclusion in the patient correspondence may help highlight the importance 
to a patient.  
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4.3 LIMITATIONS  
4.3.1 Survey and Analysis Methods  
Several limitations to the survey design were observed. The use of “ranking” questions had its 
limitations in this study. Some participants did not accurately answer these questions. It’s possible 
that this is due to lack of understanding of the directions. For instance, some individuals responded 
with an “X” for the individual(s) they believed most responsible for informing of genetic 
discoveries, instead of ranking the four providers 1-4 from most to least responsible. It is also 
possible that the inaccuracy of answers was due to the participant’s belief that no party was more 
or less responsible than another. For instance, some individuals selected “1” for all providers and 
the patient, indicating that all parties were equally responsible. Therefore, survey questions may 
or may not have been confusing for respondents. Perhaps switching between question types or 
requiring only one response for some questions and not others may have been a reason for the 
inconsistency in answers. Missing answers may reflect confusion or the lack of an appropriate 
response for respondents to select.  
Individuals participating in the surveys were also allowed to skip questions. Therefore, 
blank responses may have been an indication that respondents were “unsure” of their response and 
chose to skip the question all together.  
Specific to the patient survey, a branching format was used when inquiring whether 
participants see their primary care physicians regularly. If a participant indicated that he/she did 
not see their primary care physician or specialist regularly, they were no longer prompted to answer 
further questions about their relationship with that provider. However, patients may still have 
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shared their genetic test results with those providers and had varying opinions of the healthcare 
providers’ knowledge with the subject matter.  
Lastly, comments from participants were useful in qualitative analysis; however, they 
cannot be considered representative of the entire study population.  
4.3.2 Survey Populations  
Several limitations regarding the selected study populations were also observed. The patient 
population only included individuals tested for BRCA1/2 throughout the years of 2007-2012 at the 
University of Pittsburgh Cancer Genetics Program. These criteria limit the diversity of the study 
population. Genetic counseling practices often differ between sites across the United States, 
including the capacity for different resources and the incorporation of different institutional 
regulations for genetic testing. Differences in the cost of care in specific areas may also influence 
patients’ perspectives on genetic testing and the likelihood to pursue genetic counseling.  
In addition, the patient population included only individuals tested for BRCA1/2. While 
this represents the large majority of patients seen by the cancer genetics providers, it does not 
include the perspectives of patients seen for other hereditary cancer predisposition syndromes.  
The healthcare provider population included members of the NSGC Cancer SIG and their 
colleagues. The group is a paid-based membership that can have active members join at anytime 
and is not static. While the original estimate of the group was approximately 490 individuals, the 
number has likely fluctuated since that time. Because of this, it is difficult to assure that statistical 
significance has been met. In addition, the study population was aimed at all genetics health care 
providers; however, the NSGC Cancer SIG was primarily genetic counselors. Other providers, 
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such as medical geneticists, nurses, or others who are involved in cancer counseling could have 
been contacted as well and may have had a different perspective on the topic of recontact.  
  
  
72 
5.0  FUTURE RESEARCH OPPORTUNITIES  
Given the results of the study, many opportunities exist for future research studies. While this 
study observed the proportion of patients who share their genetic test results with other providers, 
further investigation of patients’ relationships with their primary care providers and specialists 
would be useful. A more targeted approach may include asking patients if they’ve had an in person 
conversation with their providers regarding their genetic testing results. In addition, studies 
investigating patients’ motivations behind not sharing genetic testing information with certain 
providers may be focused on more extensively, including other issues surrounding genetic testing 
(privacy, lack of interest/understanding of results, etc.).   
This study also provided insight into patients’ preferences for recontact by their genetics 
providers. Institutions already implementing recontact may find this information useful to improve 
their methods of recontact. Assessing patients’ satisfaction with these methods may be useful in 
determining their success. Furthermore, institutions that do not have a policy of recontact may 
reconsider their position.  
While this study aimed to determine differences in expectations and preferences based on 
patients with positive, negative, and inconclusive genetic test results, other factors may be 
incorporated in further studies. These may include personal cancer history and degree of risk based 
on family history (hereditary vs. familial vs. sporadic). It is possible that individuals with a 
personal history of cancer may have different perceptions of the need for recontact. Likewise, 
individuals with a strong family history of cancer may hold higher expectations for recontact 
compared to those who do not have a strong family history of cancer. Regression analysis could 
also be used to determine any trends in patient responses based on age 
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Gathering more information from institutions which do have formalized systems of 
recontact may also be useful. Further characterizing these systems by their methodologies 
(database query and direct contact vs. newsletter) should be established. This may help guide 
providers looking to develop methods of recontact.  
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6.0  CONCLUSIONS  
From this research study, we conclude that patients believe that their genetics providers have more 
responsibility to keep patients updated about new genetic discoveries than other providers and the 
patients themselves. The data supports that patients’ preferences for recontact include personalized 
letters to only appropriate patients only when new information is discovered and these preferences 
are consistent with the previous recontacting study. Financial factors influence a patient’s desire 
for additional testing and they are more likely to undergo additional genetic testing when it is free 
or costs are less than $499.  Overall, there were no differences observed between patients who 
have received positive, negative, and inconclusive BRCA1/2 test results.  
In addition, we conclude that genetics providers believe that there is some ethical duty to 
keep patients informed of new genetic testing discoveries. The majority of genetics providers have 
recontacted patients for the purpose of additional testing; however, most do not have formalized 
systems of recontact and believe that recontact should not be a standard of care practice. In 
addition, lack of resources such as limited staff, monetary support, and database access impede the 
ability for genetics providers to recontact patients and suggests that the lack of a sufficient database 
system is a significant component for genetics providers who have established formalized systems 
of recontact.  
  
75 
APPENDIX A: DIFFERENTIAL DIAGNOSES OF HEREDITARY BREAST AND OVARIAN 
CANCERS 
Genetic Syndromes Associated with Breast Cancer1 
 Gene Breast Cancer Risk Associated Cancers Associated Clinical Features 
Li-Fraumeni Syndrome TP53 30-50% 
Soft tissue sarcomas 
Osteosarcoma 
Adrenocortical tumors 
Brain tumors 
Acute leukemia 
 
Cowden Syndrome PTEN 25-50% 
Thyroid 
Uterine 
Colon 
Renal 
Mucocutaneous lesions 
Fibromas, lipomas 
Gastrointestinal hamartomas 
Macrocephaly 
Hereditary Diffuse Gastric 
Cancer 
CDH1 40% *lobular 
Stomach 
Colon 
Cleft lip and palate 
Peutz-Jegher Syndrome STK11 30-50% 
Ovarian 
Colon 
Pancreatic 
Small bowel polyposis 
Mucocutaneous 
pigmentation 
 
Genetic Syndromes Associated with Ovarian Cancer81 
 Gene  
Ovarian Cancer 
Risk 
Associated Cancers  
Associated Clinical Features  
Peutz-Jegher Syndrome STK11 18-21% 
Breast 
Colon 
Pancreatic  
Small bowel polyposis  
Mucocutaneous 
pigmentation  
Lynch Syndrome 
MLH1, 
MSH2, 
MSH6, 
PMS2, 
EPCAM 
4-11% 
Colon 
Uterine 
Stomach 
Urinary tract 
Small bowel 
Hepatobiliary  
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APPENDIX B: IRB APPROVAL LETTER 
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APPENDIX C: INFORMED CONSENT FOR HEALTHCARE PROVIDERS 
The purpose of this study is to identify methods currently practiced by cancer genetics providers 
for the purpose of recontacting patients when new genetic discoveries are made or new genetic 
testing becomes available. In addition, the study will assess genetics providers’ feelings regarding 
the duty to recontact.  Approximately 700 cancer genetics healthcare providers will be invited to 
participate in this research study. If you agree to participate, you will be asked to complete a brief, 
online survey. Completion of the survey should take no longer than 15 minutes.  
 
There is little risk involved in this study.   All results generated through the electronic survey will 
be collected anonymously. Given the nature of the topic, it is possible that some questions may 
cause distress, as some individuals may feel uncomfortable thinking about the ethical implications 
of recontacting patients. Your participation in this study is completely voluntary and you may 
choose to exit the survey at any point.  
 
There are no costs to you for participating in this study, and you will receive no direct benefit from 
participating in this study.  It is possible that information gathered from this study will be of benefit 
to the genetic counseling profession and genetics healthcare procedures utilized in the future.  
 
If you have questions about this research study, you may contact Darcy Thull, MS, CGC at (412) 
641-1466.  
 
If you have questions about your rights as a research subject, please contact the Human Subjects 
Protection Advocate at the University of Pittsburgh IRB Office, 1.866.212.2668. 
 
I have read the above information and agree to participate in this research study.  
[click accept] 
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APPENDIX D: INTRODUCTORY LETTER FOR HEALTHCARE PROVIDERS 
Dear NSGC Cancer SIG member,  
 
You are being invited to participate in a research study exploring cancer genetics providers’ 
attitudes regarding recontact of patients. You were selected as a participant because you are a 
current member of the NSGC Cancer SIG. 
 
This study is being conducted by Michelle O’Connor, a genetic counseling student at the 
University of Pittsburgh, under the direction of Darcy Thull, MS, CGC and Natalie Carter, MS, 
CGC. The study has IRB approval through the University of Pittsburgh.  
 
The purpose of this study is to identify methods currently practiced by cancer genetics providers 
for recontacting patients when additional genetic testing options become available. In addition, we 
hope to better understand genetics providers’ preferences and attitudes regarding the duty to 
recontact.  
 
Previous studies have suggested mixed preferences from those working in the field of genetics 
regarding the responsibly to recontact patients. We wish to revisit this topic due to the complex 
and rapid emergence of new genetic technologies.  
 
Participation in this study involves an online, anonymous survey that should take approximately 
15 minutes to complete. Your participation is voluntary and you may choose to exit the survey at 
any point.  
 
The survey link is ______________. 
 
Responses are kindly requested by ________________. 
 
Please feel free to contact us with any questions or concerns.  
 
Thank you for your time, 
 
Michelle O’Connor, BS 
 
Darcy Thull, MS, CGC 
 
Natalie Carter, MS, CGC 
  
79 
APPENDIX E: QUESTIONNAIRE FOR HEALTHCARE PROVIDERS 
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APPENDIX F: INTRODUCTORY LETTER FOR PATIENTS  
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 APPENDIX G: INFORMED CONSENT FOR PATIENTS 
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 APPENDIX H: QUESTIONNAIRE FOR PATIENTS 
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APPENDIX I: ADDITIONAL TABLES 
Aim 1: Patient Population 
Table 24. Patient Relationships with PCP and Specialist 
         
 Do you see a PCP regularly?   
Do you see a specialist 
regularly? 
 n=254 Responses %   n=254 Responses % 
 No 26 10.24   No 50 19.69 
 Yes 228 89.76   Yes 203 79.92 
 Unsure 0 0.00   Unsure 1 0.39 
         
 
Have you shared your 
genetic testing results?   
Have you shared your 
genetic results? 
 n=228 Responses %   n=203 Responses % 
 No 52 22.81   No 6 2.96 
 Yes 169 74.12   Yes 194 95.57 
 Unsure 7 3.07   Unsure 3 1.48 
         
         
 
Did not share results with 
PCP   
Did not share results with 
specialist 
Do you feel 
your PCP is 
knowledgeable 
regarding your 
genetic 
health? 
n=52 Responses %  
Do you feel 
your 
specialists is 
knowledgeable 
regarding your 
genetic 
health? 
n=6 Responses % 
No 36 69.23  No 1 16.67 
Yes 14 26.92  Yes 5 83.33 
Unsure 2 3.85  Unsure 0 0.00 
Did share results with PCP  
Did share results with 
specialist 
n=169 Responses %  n=194 Responses % 
No 37 21.89  No 8 4.12 
Yes 123 72.78  Yes 186 95.88 
Unsure 9 5.33  Unsure 0 0.00 
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Table 25. Sharing of Genetic Test Results with Specialist vs. Perceived Specialist Knowledge by Patients  
   
Shared genetic test 
results with specialist 
    No  (%) Yes (%) 
Do you feel your specialist is 
knowledgeable regarding 
genetic health 
N=200 
No 1 (0.5) 8 (4.0) 
Yes  5 (2.5) 186 (93.0) 
  p-value  0.1032   
 
Table 26. Perceived PCP Knowledge vs. Perceived Responsibility for Recontact According to Patients  
  Responsibility for Recontact  
Felt that PCP 
was 
knowledgeable 
n=164  
  GC (%) 
Specialist 
(%) PCP (%) Patient (%) 
No  22 (13.4) 26 (15.8) 5 (3.0) 2 (1.2) 
Yes 57 (34.7) 36 (21.9) 5 (3.0) 11 (6.7) 
p-value =0.1001      
      
Comparison of Questionnaire Responses between BRCA Results Groups  
Table 27. Perceived Primary Responsibility for Recontact by Patients vs. BRCA Result 
n=194 
Patient 
(%) PCP (%) 
Specialist 
(%)  GC (%) 
Negative  8 (4.1) 9 (4.6)  58 (29.8) 74 (38.1) 
Positive  7 (3.6) 1 (0.5) 14 (7.2) 15 (7.7) 
VUS 0 (0.0)  0 (0.0) 3 (1.5) 5 (2.5) 
p-value  0.142    
 
Table 28. Preferred Timeframe for Recontact vs. BRCA Result 
 n=247 
Regularly, even if no 
new discoveries made 
(%) 
When any new 
discoveries are made 
(%) 
When new discoveries are made 
that directly pertain to patient 
(%) 
Negative 50 (20.2) 39 (15.7) 101 (40.8) 
Positive 22 (8.9) 7 (2.8) 17 (6.8) 
VUS 4 (1.6) 2 (0.8) 5 (2.0) 
p-value  0.084   
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Table 29. Preferred Method of Recontact vs. BRCA Result 
 n=254 
Generalize
d letter to 
all patients 
(%) 
Telephon
e (%) 
Media 
Release 
(%) 
Email 
(%) 
Letter to 
appropriate 
patients (%) 
News-
letter 
(%) 
Website 
(%) 
No 
answer 
(%) 
Negativ
e  21 (8.2) 13 (5.1) 0 (0.0) 15 (5.9) 130 (51.1) 2 (0.7) 1 (0.3) 12 (4.7) 
Positive  7 (2.7) 4 (1.5) 0 (0.0) 7 (2.7) 26 (10.2) 1 (0.3) 0 (0.0) 4 (1.5) 
VUS 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 9 (3.5) 0 (0.0) 0 (0.0) 1 (0.3) 
p-value 0.739        
 
Table 30. Preferred Information Included in Recontact vs. BRCA Result 
n=254 
New information is 
available; ask 
patient to contact 
genetics if 
interested in more 
information (%) 
New information is 
available; identify 
resource where 
more information is 
available (%) 
Generally what 
information has 
been identified 
(%) 
Specifically 
what 
information has 
been identified  
(%) 
No 
answer 
(%)  
Negative 24 (9.4) 20 (7.8) 13 (5.1) 128 (50.3) 9 (3.5) 
Positive 2 (0.7) 9 (3.5) 6 (2.3) 30 (11.8) 2 (0.7) 
VUS 2 (0.7) 1 (0.3) 0 (0.0) 7 (2.7) 1 (0.3) 
p-value 0.253     
 
Table 31. Preferences for Contract for Recontact vs. BRCA Result 
 n=249 No (%) Yes (%) 
Negative 6 (2.4) 186 (74.6) 
Positive 0 (0.0) 46 (18.4) 
VUS 0 (0.0) 11 (4.4) 
p-value 0.401  
 
Table 32. Circumstances to Recontact Regardless of Patients Preference vs. BRCA Result 
 n=226 No  (%) Yes (%) 
Negative 25 (11.0) 152 (67.2) 
Positive  5 (2.2) 34 (15.0) 
VUS 0 (0.0) 10 (4.4) 
p-value  0.439  
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Table 33. Reasons to be Recontacted vs. BRCA Result 
  
  
Negative 
(%) Positive (%)  VUS (%) P-value  
Receive ongoing support 
n=207 
No  103 (49.7) 17 (8.2) 5 (2.4) 
0.08 
Yes 59 (28.5) 21 (10.1)  2 (0.9)  
New information that impacts my health 
n=242 
No  1 (0.4) 0 (0.0) 0 (0.0) 
0.878 
Yes 184 (76.0) 46 (19.0) 11 (4.5) 
New information about cancer screening 
n=224 
No  24 (10.7) 2 (0.8) 2 (0.8) 
0.171 
Yes 148 (66.0) 41 (18.3) 7 (3.1) 
New information about  personal cancer 
risk 
n=237 
No  3 (1.2) 1 (4.2)  0 (0.0) 
0.876 
Yes 180 (75.9) 43 (18.1) 10 (4.2) 
New information about cancer risk for 
family members 
n=237 
No  12 (5.0) 1 (4.2) 0 (0.0 ) 
0.378 
Yes 170 (71.7) 43 (18.1) 11 (4.6) 
Reinforce decision making  
n=215 
No  62 (28.8) 13 (6.0) 3 (1.3) 
0.914 
Yes 106 (49.3) 26 (12.0) 5 (2.3) 
Relationship with Genetics Provider 
n=206 
No  107 (51.9) 19 (9.2) 4 (1.9) 
0.072 
Yes 52 (25.2)  20 (9.7) 4 (1.9) 
New information is interesting  
n=211 
No  117 (55.4) 20 (9.4)  6 (2.8) 
0.05 
Yes 47 (22.2) 19 (9.0) 2 (0.9) 
 
Table 34. Patients Desire for Recontact and Required Additional Genetics Consultation vs. BRCA Result 
 N=245 No  (%) Yes (%) 
Negative 157 (64.0) 30 (12.2) 
Positive 43 (17.5) 4 (1.6) 
VUS 9 (3.6) 2 (0.8) 
P-value 0.4  
 
Table 35. Patient Recall of Recontact Recommendations vs. BRCA Result 
 N=224 No (%) Yes (%) 
Negative 103 (45.9) 67 (29.9) 
Positive  26 (11.6) 17 (7.5) 
VUS 6 (2.6) 5 (2.2) 
p-value  0.92  
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Aim 2: Genetics Provider Population 
Table 36. Perceived Patient Responsibility vs. Routine Recommendation to Recontact 
 
 Patient responsibility  P-value 
 N=193   
None 
(%) Some (%) High (%)  
0.65 
Routinely direct to 
recontact 
No 0 (0.0) 4 (2.0) 15 (7.7) 
Yes 1 (0.5) 53 (27.4) 
120 
(62.1) 
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APPENDIX J: ADVISORY COMMITTEE 
Thesis Advisor: Darcy Thull, MS, CGC, Certified Genetic Counselor, Cancer Genetics 
Program, University of Pittsburgh Medical Center 
 
Thesis Committee Member: Francesmary Modugno, Ph.D, Adjunct Assistant Professor, 
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh 
 
Thesis Committee Member: M. Michael Barmada, Ph.D., Associate Professor, Department of 
Human Genetics, Graduate School of Public Health, University of Pittsburgh 
 
Advisory Committee Member: Natalie Carter, MS, CGC, Certified Genetic Counselor, Cancer 
Genetics Program, University of Pittsburgh Medical Center 
 
Advisory Committee Member: Kristin Zorn, MD, Assistant Professor, Department of 
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Advisory Committee Member: Robin E. Grubs, Ph.D., CGC, Assistant Professor, Department 
of Human Genetics, Graduate School of Public Health, University of Pittsburgh  
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Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh  
  
97 
BIBLIOGRAPHY 
1. Shannon, K.M., and Chittenden, A. (2012). Genetic testing by cancer site: breast. Cancer journal 
18, 310-319. 
2. Petrucelli, N., Daly, M.B., and Feldman, G.L. (2010). Hereditary breast and ovarian cancer due 
to mutations in BRCA1 and BRCA2. Genetics in medicine : official journal of the American 
College of Medical Genetics 12, 245-259. 
3. Myriad Genetic Laboratories.  (2014). BRACAnalysis By the Numbers. Available at: 
https://www.myriad.com/about-myriad/media-center/bracanalysis-by-the-numbers-2/ 
4. NCCN Clinical Practice Guidelines in Oncology. (2013). Genetic/Familial High Risk 
Assessment: Breast and Ovarian (v.4.2013 HEREDITARY BREAST AND/OR 
OVARIAN SYNDROME) Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf 
5. Hirschhorn, K., Fleisher, L.D., Godmilow, L., Howell, R.R., Lebel, R.R., McCabe, E.R., 
McGinniss, M.J., Milunsky, A., Pelias, M.Z., Pyeritz, R.E., et al. (1999). Duty to re-
contact. Genetics in medicine : official journal of the American College of Medical 
Genetics 1, 171-172. 
6. American Cancer Society (2013). Breast cancer overview. 
http://www.cancer.org/cancer/breastcancer/overviewguide, accessed 1/14 
7. Schneider, K.A. (2012). Counseling about cancer : strategies for genetic counseling.(Hoboken, 
N.J.: Wiley-Blackwell). 
8. Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S.C., Manley, S., 
Culver, J.O., Acton, R., Larsen-Haidle, J., et al. (2004). Genetic cancer risk assessment and 
counseling: recommendations of the national society of genetic counselors. Journal of 
genetic counseling 13, 83-114. 
9. American Cancer Society (2013). Breast cancer in men. 
http://www.cancer.org/cancer/breastcancerinmen/index, accessed 1/14 
10. American Cancer Society (2013). Ovarian cancer overview. 
http://www.cancer.org/cancer/ovariancancer/index, accessed 1/14   
11. Claus, E.B., Schildkraut, J.M., Thompson, W.D., and Risch, N.J. (1996). The genetic 
attributable risk of breast and ovarian cancer. Cancer 77, 2318-2324. 
12. Hulka, B.S., and Moorman, P.G. (2001). Breast cancer: hormones and other risk factors. 
Maturitas 38, 103-113; discussion 113-106. 
13. Lambe, M., Hsieh, C., Trichopoulos, D., Ekbom, A., Pavia, M., and Adami, H.O. (1994). 
Transient increase in the risk of breast cancer after giving birth. The New England journal 
of medicine 331, 5-9. 
14. Collaborative Group on Hormonal Factors in Breast, C. (2002). Breast cancer and 
breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies 
in 30 countries, including 50302 women with breast cancer and 96973 women without the 
disease. Lancet 360, 187-195. 
15. Collaborative Group on Hormonal Factors in Breast, C. (1996). Breast cancer and hormonal 
contraceptives: collaborative reanalysis of individual data on 53 297 women with breast 
  
98 
cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 
347, 1713-1727. 
16. (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 
51 epidemiological studies of 52,705 women with breast cancer and 108,411 women 
without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 
350, 1047-1059. 
17. Oppong, B.A., and King, T.A. (2011). Recommendations for women with lobular carcinoma 
in situ (LCIS). Oncology 25, 1051-1056, 1058. 
18. Hartmann, L.C., Sellers, T.A., Frost, M.H., Lingle, W.L., Degnim, A.C., Ghosh, K., Vierkant, 
R.A., Maloney, S.D., Pankratz, V.S., Hillman, D.W., et al. (2005). Benign breast disease 
and the risk of breast cancer. The New England journal of medicine 353, 229-237. 
19. Ginsburg, O.M., Martin, L.J., and Boyd, N.F. (2008). Mammographic density, lobular 
involution, and risk of breast cancer. British journal of cancer 99, 1369-1374. 
20. Shannon, K.M., Rodgers, L.H., Chan-Smutko, G., Patel, D., Gabree, M., and Ryan, P.D. 
(2011). Which individuals undergoing BRACAnalysis need BART testing? Cancer 
genetics 204, 416-422. 
21. Hoover, R.N., Hyer, M., Pfeiffer, R.M., Adam, E., Bond, B., Cheville, A.L., Colton, T., Hartge, 
P., Hatch, E.E., Herbst, A.L., et al. (2011). Adverse health outcomes in women exposed in 
utero to diethylstilbestrol. The New England journal of medicine 365, 1304-1314. 
22. Singletary, K.W., and Gapstur, S.M. (2001). Alcohol and breast cancer: review of 
epidemiologic and experimental evidence and potential mechanisms. JAMA : the journal 
of the American Medical Association 286, 2143-2151. 
23. Collaborative Group on Hormonal Factors in Breast, C. (2001). Familial breast cancer: 
collaborative reanalysis of individual data from 52 epidemiological studies including 
58,209 women with breast cancer and 101,986 women without the disease. Lancet 358, 
1389-1399. 
24. Whittemore, A.S., Harris, R., and Itnyre, J. (1992). Characteristics relating to ovarian cancer 
risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian 
cancers in white women. Collaborative Ovarian Cancer Group. American journal of 
epidemiology 136, 1184-1203. 
25. Hunn, J., and Rodriguez, G.C. (2012). Ovarian cancer: etiology, risk factors, and 
epidemiology. Clinical obstetrics and gynecology 55, 3-23. 
26. Danforth, K.N., Tworoger, S.S., Hecht, J.L., Rosner, B.A., Colditz, G.A., and Hankinson, S.E. 
(2007). Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer causes 
& control : CCC 18, 517-523. 
27. Rodriguez, C., Patel, A.V., Calle, E.E., Jacob, E.J., and Thun, M.J. (2001). Estrogen 
replacement therapy and ovarian cancer mortality in a large prospective study of US 
women. JAMA : the journal of the American Medical Association 285, 1460-1465. 
28. Lin, H.W., Tu, Y.Y., Lin, S.Y., Su, W.J., Lin, W.L., Lin, W.Z., Wu, S.C., and Lai, Y.L. (2011). 
Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based 
study. The lancet oncology 12, 900-904. 
29. Munksgaard, P.S., and Blaakaer, J. (2011). The association between endometriosis and 
gynecological cancers and breast cancer: a review of epidemiological data. Gynecologic 
oncology 123, 157-163. 
30. Cibula, D., Widschwendter, M., Majek, O., and Dusek, L. (2011). Tubal ligation and the risk 
of ovarian cancer: review and meta-analysis. Human reproduction update 17, 55-67. 
  
99 
31. Huncharek, M., Geschwind, J.F., and Kupelnick, B. (2003). Perineal application of cosmetic 
talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from 
sixteen observational studies. Anticancer research 23, 1955-1960. 
32. Kerber, R.A., and Slattery, M.L. (1995). The impact of family history on ovarian cancer risk. 
The Utah Population Database. Archives of internal medicine 155, 905-912. 
33. Schildkraut, J.M., Risch, N., and Thompson, W.D. (1989). Evaluating genetic association 
among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer 
relationship. American journal of human genetics 45, 521-529. 
34. American College of, O., Gynecologists, Bulletins--Gynecology, A.C.o.P., Genetics, A.C.o., 
and Society of Gynecologic, O. (2009). ACOG Practice Bulletin No. 103: Hereditary breast 
and ovarian cancer syndrome. Obstetrics and gynecology 113, 957-966. 
35. Roa, B.B., Boyd, A.A., Volcik, K., and Richards, C.S. (1996). Ashkenazi Jewish population 
frequencies for common mutations in BRCA1 and BRCA2. Nature genetics 14, 185-187. 
36. Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., and King, M.C. 
(1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 
1684-1689. 
37. Rosen, E.M., Fan, S., and Ma, Y. (2006). BRCA1 regulation of transcription. Cancer letters 
236, 175-185. 
38. Deng, C.X. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response 
and cancer evolution. Nucleic acids research 34, 1416-1426. 
39. Venkitaraman, A.R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. 
Cell 108, 171-182. 
40. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, 
S., Gumbs, C., and Micklem, G. (1995). Identification of the breast cancer susceptibility 
gene BRCA2. Nature 378, 789-792. 
41. Walsh, T., Casadei, S., Coats, K.H., Swisher, E., Stray, S.M., Higgins, J., Roach, K.C., 
Mandell, J., Lee, M.K., Ciernikova, S., et al. (2006). Spectrum of mutations in BRCA1, 
BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA : the journal of 
the American Medical Association 295, 1379-1388. 
42. Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Loman, N., 
Olsson, H., Johannsson, O., Borg, A., et al. (2003). Average risks of breast and ovarian 
cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for 
family history: a combined analysis of 22 studies. American journal of human genetics 72, 
1117-1130. 
43. Gao, X., Fisher, S.G., and Emami, B. (2003). Risk of second primary cancer in the contralateral 
breast in women treated for early-stage breast cancer: a population-based study. 
International journal of radiation oncology, biology, physics 56, 1038-1045. 
44. Breast Cancer Linkage, C. (1999). Cancer risks in BRCA2 mutation carriers. Journal of the 
National Cancer Institute 91, 1310-1316. 
45. American Cancer Society (2014). Lifetime Risk of Developing or Dying From Cancer. 
http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-
from-cancer, accessed 1/14 
46. Tai, Y.C., Domchek, S., Parmigiani, G., and Chen, S. (2007). Breast cancer risk among male 
BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 99, 1811-
1814. 
  
100 
47. Rakha, E.A., Reis-Filho, J.S., and Ellis, I.O. (2008). Basal-like breast cancer: a critical review. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
26, 2568-2581. 
48. Riley, B.D., Culver, J.O., Skrzynia, C., Senter, L.A., Peters, J.A., Costalas, J.W., Callif-Daley, 
F., Grumet, S.C., Hunt, K.S., Nagy, R.S., et al. (2012). Essential elements of genetic cancer 
risk assessment, counseling, and testing: updated recommendations of the National Society 
of Genetic Counselors. Journal of genetic counseling 21, 151-161. 
49. Weitzel, J.N., Lagos, V.I., Cullinane, C.A., Gambol, P.J., Culver, J.O., Blazer, K.R., 
Palomares, M.R., Lowstuter, K.J., and MacDonald, D.J. (2007). Limited family structure 
and BRCA gene mutation status in single cases of breast cancer. JAMA : the journal of the 
American Medical Association 297, 2587-2595. 
50. Berry, D.A., Parmigiani, G., Sanchez, J., Schildkraut, J., and Winer, E. (1997). Probability of 
carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal 
of the National Cancer Institute 89, 227-238. 
51. Frank, T.S., Deffenbaugh, A.M., Reid, J.E., Hulick, M., Ward, B.E., Lingenfelter, B., 
Gumpper, K.L., Scholl, T., Tavtigian, S.V., Pruss, D.R., et al. (2002). Clinical 
characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 
10,000 individuals. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 20, 1480-1490. 
52. Berliner, J.L., Fay, A.M., Cummings, S.A., Burnett, B., and Tillmanns, T. (2013). NSGC 
practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian 
cancer. Journal of genetic counseling 22, 155-163. 
53. American Society of Clinical, O. (2003). American Society of Clinical Oncology policy 
statement update: genetic testing for cancer susceptibility. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 21, 2397-2406. 
54. Kalyvas, J., and Little, A.S. (2013). Invalidating human gene patenting: the U.S. Supreme 
Court rules in Association for Molecular Pathology v. Myriad Genetics. World 
neurosurgery 80, 680-681. 
55. Judkins, T., Rosenthal, E., Arnell, C., Burbidge, L.A., Geary, W., Barrus, T., Schoenberger, J., 
Trost, J., Wenstrup, R.J., and Roa, B.B. (2012). Clinical significance of large 
rearrangements in BRCA1 and BRCA2. Cancer 118, 5210-5216. 
56. Eggington, J.M. (2012). Current Variant of Uncertain significance rates in BRCA1/2 and 
Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EPCAM). Poster presented at 
American College of Medical Genetics Annual Meeting 
57. Allain, D.C., Friedman, S., and Senter, L. (2012). Consumer awareness and attitudes about 
insurance discrimination post enactment of the Genetic Information Nondiscrimination 
Act. Familial cancer 11, 637-644. 
58. Cole, L.J., and Fleisher, L.D. (2003). Update on HIPAA privacy: are you ready? Genetics in 
medicine : official journal of the American College of Medical Genetics 5, 183-186. 
59. Halbert, C.H., Stopfer, J.E., McDonald, J., Weathers, B., Collier, A., Troxel, A.B., and 
Domchek, S. (2011). Long-term reactions to genetic testing for BRCA1 and BRCA2 
mutations: does time heal women's concerns? Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology 29, 4302-4306. 
60. Schwartz, M.D., Peshkin, B.N., Hughes, C., Main, D., Isaacs, C., and Lerman, C. (2002). 
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based 
sample. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 20, 514-520. 
  
101 
61. Wagner, T.M., Moslinger, R., Langbauer, G., Ahner, R., Fleischmann, E., Auterith, A., 
Friedmann, A., Helbich, T., Zielinski, C., Pittermann, E., et al. (2000). Attitude towards 
prophylactic surgery and effects of genetic counselling in families with BRCA mutations. 
Austrian Hereditary Breast and Ovarian Cancer Group. British journal of cancer 82, 1249-
1253. 
62. Murray, M.L., Cerrato, F., Bennett, R.L., and Jarvik, G.P. (2011). Follow-up of carriers of 
BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical 
decisions. Genetics in medicine : official journal of the American College of Medical 
Genetics 13, 998-1005. 
63. Uhlmann, W.R., Schuette, J.L., and Yashar, B.M. (2009). A guide to genetic 
counseling.(Hoboken, N.J.: Wiley-Blackwell). 
64. Richards, C.S., Bale, S., Bellissimo, D.B., Das, S., Grody, W.W., Hegde, M.R., Lyon, E., 
Ward, B.E., and Molecular Subcommittee of the, A.L.Q.A.C. (2008). ACMG 
recommendations for standards for interpretation and reporting of sequence variations: 
Revisions 2007. Genetics in medicine : official journal of the American College of Medical 
Genetics 10, 294-300. 
65. O'Neill, S.C., Rini, C., Goldsmith, R.E., Valdimarsdottir, H., Cohen, L.H., and Schwartz, M.D. 
(2009). Distress among women receiving uninformative BRCA1/2 results: 12-month 
outcomes. Psycho-oncology 18, 1088-1096. 
66. Rubinstein, W.S. (2008). Roles and responsibilities of a medical geneticist. Familial cancer 7, 
5-14. 
67. Meldrum, C., Doyle, M.A., and Tothill, R.W. (2011). Next-generation sequencing for cancer 
diagnostics: a practical perspective. The Clinical biochemist Reviews / Australian 
Association of Clinical Biochemists 32, 177-195. 
68. Hiraki, S., Rinella, E.S., Schnabel, F., Oratz, R., and Ostrer, H. (2014). Cancer Risk 
Assessment Using Genetic Panel Testing: Considerations for Clinical Application. Journal 
of genetic counseling. 
69. Tan YY, N.L., McGaughran JM, Spurdle AB, Obermair. (2013). Referral of Patients with 
Suspected Hereditary Breast-Ovarian Cancer or Lynch Syndrome for Genetic Services: A 
Systematic Review. J Community Med Health Educ. 
70. Murff, H.J., Byrne, D., and Syngal, S. (2004). Cancer risk assessment: quality and impact of 
the family history interview. American journal of preventive medicine 27, 239-245. 
71. Teng, I., and Spigelman, A. (2013). Attitudes and knowledge of medical practitioners to 
hereditary cancer clinics and cancer genetic testing. Familial cancer. 
72. Sharpe, N.F., and Carter, R.F. (2006). Genetic testing : care, consent, and liability.(Hoboken, 
N.J.: Wiley-Liss). 
73. Evans, H.M. (2007). Do patients have duties? Journal of medical ethics 33, 689-694. 
74. Fitzpatrick, J.L., Hahn, C., Costa, T., and Huggins, M.J. (1999). The duty to recontact: attitudes 
of genetics service providers. American journal of human genetics 64, 852-860. 
75. Pelias, M.Z. (1991). Duty to disclose in medical genetics: a legal perspective. American journal 
of medical genetics 39, 347-354. 
76. Hunter, A.G., Sharpe, N., Mullen, M., and Meschino, W.S. (2001). Ethical, legal, and practical 
concerns about recontacting patients to inform them of new information: the case in 
medical genetics. American journal of medical genetics 103, 265-276. 
77. Hampel, H. (2009). Recontacting patients who have tested negative for BRCA1 and BRCA2 
mutations: how, who and why? Journal of genetic counseling 18, 527-529. 
  
102 
78. Andorno, R. (2004). The right not to know: an autonomy based approach. Journal of medical 
ethics 30, 435-439; discussion 439-440. 
79. Krejcie, R.V., and Morgan, D.W., (1970). Determining sample size for research activite. 
Educational and Phychological Measurement 
80. Grimshaw, J.M., and Russell, I.T. (1993). Effect of clinical guidelines on medical practice: a 
systematic review of rigorous evaluations. Lancet 342, 1317-1322. 
81. Weissman, S.M., Weiss, S.M., and Newlin, A.C. (2012). Genetic testing by cancer site: ovary. 
Cancer journal 18, 320-327. 
 
 
 
